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        Squamous cell carcinoma of head and neck (SCCHN) is the tenth most common 
cancer in the world. Unfortunately, the survival of patients with SCCHN has not 
improved in the last 40 years. Therefore new targets for therapy are needed, and to this 
end we are studying signaling pathways activated by IL-6 which we have found 
stimulates cell migration and soft agar growth in SCCHN.  Our data show that IL-6 
increases TWIST expression in a transcription-independent mechanism in many SCCHN 
cell lines. Further investigation reveals TWIST can be phosphorylated upon IL-6 
treatment. By computation prediction ( http://scansite.mit.edu/motifscan_seq.phtml ), we 
found that TWIST has a putative phosphorylation site for casein kinase 2 (CK2) 
suggesting that this kinase could serve as a link between IL-6 stimulation and Twist 
stability.  To test this hypothesis, we used a CK2 inhibitor and shRNA to CK2 and found 
that these interventions inhibited IL-6 stimulation of TWIST stability.  In addition, 
mutation of the putative CK2 phosphorylation site (S18/S20A) in TWIST decreased the 
amount of phospho-ATP incorporated by TWIST in an in vitro kinase assay, and altered 
TWIST stability. In Boyd chamber migration assay and wound-healing assay, the CK2 
inhibitor, DMAT, was found to decrease the motility of IL-6 stimulated SCCHN cells 
 viii
and over expression of either a wild-type or the hyperphosphorylated mimicking mutant 
S18/20D –Twist rather than the hypo-phosphorylated mimicking mutant S18/20A-Twist 
can promote SCCHN cell motility.To our knowledge, this is the first report to identify the 
importance of IL-6 stimulated CK2 phosphorylation of TWIST in SCCHN. As CK2 
inhibitors are currently under phase I clinical trials, our findings indicate that CK2 may 
be a viable therapeutic target in SCCHN. Therefore, further pre-clinical studies of this 
inhibitor are underway. 
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Introduction 
I. Introduction 
1.1. Overview of Genetic Pathogenesis of Squamous Cell Carcinoma of Head and 
Neck (SCCHN)  
 
        Squamous cell carcinoma of head and neck (SCCHN) arises from the mucosa of the 
upper aerodigestive tract (UADT) and accounts for >90% of cancers arising from the 
head and neck region.  The UADT consists of six major sites including the oral cavity, 
oropharynx, larynx, hypopharynx, the nose and paranasal sinuses, and the nasopharynx 
(Figure 1.1).  Taking cancers arising from these sites in aggregate, SCCHN is the sixth 
most common cancer in the world and accounts for 3.2 percent of all malignancies in the 
United States. In the US, about 48,010 Americans develop SCCHN annually and about 
11,260 die from the disease. Males are affected significantly more often than females 
with a ratio ranging from 2:1 to 4:1 (Parkin et al., 2005; Jemal et al., 2009). Despite the 
progress in surgery, radiation and chemotherapies that have enhanced organ preservation, 
survival of SCCHN patients has improved only minimally in the last 40 years. Recent 
advances in understanding the risk factors and molecular events involved in the 
pathogenesis of SCCHN have provided a foundation for development of new methods for 
risk stratification, patient screening, prevention and therapy.  
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Figure 1.1 Anatomy of head and neck  
Head and neck region can be further divided into several parts where SCCHN can 
develop: (1) The oral cavity includes the lip, floor of mouth, tongue, hard palate and 
buccal mucosa; (2) The pharynx includes oropharynx, nasopharynx and hypopharynx;   
(3) the larynx includes the supraglottic, glottic, and subglottic larynx. (4) nasal cavity.  
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1.1.1 Risk Factors for Development of SCCHN  
        Tobacco smoking and alcohol consumption are the major risk factors for developing 
SCCHN (Spitz, 1994). Up to 80% of SCCHN patients have been exposed to smoking or 
alcohol (Sankaranarayanan et al., 1998). Compared to non-smokers, there is a 5- to 25-
fold increased risk in heavy smokers (Blot et al., 1988).  
        Betel nut chewing is another important risk factor in the certain regions of Asia, 
including the Indian subcontinent and Taiwan, where there is a higher SCCHN endemic 
rate. It can be an independent risk factor for developing SCCHN or work synergistically 
with smoking and alcohol (Lee et al., 2005). Chronic viral infection is also an important 
risk factor for head and neck cancer. Human pappilomavirus (HPV) has recently been 
found to be associated with the development of SCCHN arising within the tonsil and base 
of tongue subsites of the oropharynx (D'Souza et al., 2007). There are emerging data 
showing HPV-related SCCHN tends to have better prognosis relative to HPV-negative 
cancers (Fakhry et al., 2008). The vast majority of nasopharyngeal cancers are associated 
with the Epstein-Barr Virus (EBV) and these tumors are major causes of cancer 
morbidity and mortality in Southern China, Taiwan, and Hong Kong (Young & 
Rickinson, 2004).  Other risk factors include occupational exposure to chemicals, prior 
radiation for malignant or benign disease (Sale et al., 2004), genetic factors, poor oral 
hygiene and periodontal disease (Tezal et al., 2007; Tezal et al., 2009).  
 
 
 4
Introduction 
 
1.1.2  SCCHN Carcinogenesis   
        The chronic exposure of the upper aerodigestive tract to the aformentioned risk 
factors leads to accumulation of genetic abnormalities in the epithelial cells that line the 
mucosal surfaces of head and neck region, leading to the transformation of normal 
squamous mucosa to pre-malignant dysplastic lesions and eventually invasive cancers.  
        Pathologically, the process can be divided into several steps including normal 
mucosa, hyperplasia, dysplasia, carcinoma in situ and cancer as illustrated in Figure 1.2. 
A retrospective study of 97 cases of with epithelial dysplasia in the head and neck 
mucosa demonstrated that 50% of patients developed carcinoma within a 30-month of 
follow-up, lending support to  the multi-step carcinogenesis model. (Partridge et al., 
2001; Bosatra et al., 1997). Cells injured by exposure to carcinogens may undergo an 
irreversible genetic damage and cell death or undergo DNA repair and survive and 
propogate these genetic abnormalities. The surviving cells often acquire increased 
resistance to apoptosis, continue proliferation, migrate and heal the area of injury. With 
repeated injury, the proliferating cells may accumulate to produce a thickened epithelium, 
termed hyperplasia. If the mutagen exposure persists, further irreversible genetic 
mutations and epigenetic changes may occur with changes of not only the number but 
also the morphology of proliferating cells, which result in dysplasia or carcinoma in situ 
(CIS). Dysplasia and CIS lesions are premalignant. With continued growth, the 
transformed cells can acquire the ability to invade and migrate through the basement 
membrane into the stroma, which defines the lesion as an invasive carcinoma.  
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Hyperplasia, dysplasia, or CIS may be accompanied by hyper-keratinization, which may 
be visible clinically as leukoplakia.  When they are accompanied with a progressive 
increase in inflammation and proliferation of fibrous stroma, which may be visible 
clinically as induration and vascular erythema, called erythroplasia.  
 
1.1.3 The Muli-step Model of SCCHN Carcinogenesis  
        Carcinogenesis occurs as a result of multiple sequential alterations to the DNA of 
epithelial cells that impact the quantitative and qualitative expression of multiple genes 
involved in regulation of cell proliferation, survival, invasion and other hallmarks of 
cancer (Hanahan and Weinberg, 2000). An “allelogram” model of genetic progression in 
SCCHN carcinogeneis was proposed by Califano et al (Figure 1.2),  which was based on 
microsatellite analysis of patient specimens in which the abnormal mucosa cells 
surrounding invasive cancers harbored similar genetic losses to the tumor cells (Califano 
et al., 1996; Califano et al., 2000). In this model, loss of 9p, which results in inactivation 
of the p16 and p14 ARF tumor suppressor genes, was a very early event, during the 
transition from normal mucosa to benign squamous hyperplasia. This was frequently 
followed by loss of 3p (the site of potential tumor suppressor genes, including FHIT 
[fragile histidine triad] and RASSF1A) and 17p (site of the p53 tumor suppressor gene) 
with the transition at the histologic level to dysplasia. At later stages, the transition from 
dysplasia to carcinoma in situ was commonly associated with specific additional losses 
(11q, 13q, 14q) and further losses at (6p, 8p, 4q) were found in the transition to invasive  
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squamous cell carcinoma. This model were confirmed and expanded upon by other 
researchers using different techniques such as comparative genomic hybridization 
(Bockmuhl et al., 1998). In summary, the most frequent cytogenetic alterations in 
SCCHN are gains at the 3q,8q,9q, 20q, 7p,11q13 and 5p chromosomal regions and losses 
of 3p,9p,21q,5q,13q,18q and 8p (Gollin, 2001). Several findings observed in the first 
models such as 17p13 loss, 14q24 loss and 6p loss have not been observed to occur at 
high frequency in classical or molecular cytogenetic methods. Recent studies of 
chromosomal gain and loss in SCCHN are summarized in Figure 1.2. Despite the 
discrepancies between studies and controversies, the classical view of genetic progression 
provided useful information to examine the tumor biology and molecular events in 
SCCHN.   
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Figure 1.2  
Summary of the pathologic and molecular carcinogenesis of SCCHN  
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1.2 A contemporary overview of the molecular pathogenesis of SCCHN and a brief 
review of molecularly targeted therapy of SCCHN  
        The development of cancer from normal epithelial requires the acquisition of 6 
hallmarks including (1) self-sufficiency in growth signals, (2)  insensitivity to antigrowth 
signals, (3)  evading apoptosis, (4) limitless replicative potential, (5) sustained 
angiogenesis, and (6) tissue invasion and metastasis (Hanahan and Weinberg, 2000). 
These hallmarks lead to dysregulation of gene expression profiles and disruption of 
molecular networks.  Weinberg has shown that molecular alterations in the expression or 
function of at least two genes is required to alter important cellular functions and 
transform normal rodent cells to tumors under experimental conditions, while the human 
counterparts are more difficult to transform (Hahn and Weinberg, 2002). One important 
requirement for neoplastic transformation is to acquire the ability of uncontrolled cell 
proliferation. In the past decades, numerous efforts have been spent to study the SOS-
Ras-Raf-MAP kinase mitogenic cascade (SOS: son of sevenless homolog), the central 
pathway controlling cell proliferation. In the model, the increased proliferation and 
concomitant cell-cycle progression can result from activation of Ras, which can be 
activated by viral infection, mutation, or by upstream signal activation due to over 
expression of the growth factors or receptors, such as epidermal growth factor receptor 
(EGFR). Upon Ras activation, many of downstream proteins related to cell proliferation 
or the cell-cycle entry such as MAPKs (mitogen activated protein kinases), AP-1 
(transcription factor activator protein-1) and cyclin D1 are activated. However, Ras  
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activation and increased proliferation alone are not sufficient to cause tumor 
transformation because these proliferating cells eventually undergo apoptosis or 
senescence (Bennecke et al., 2010). Additional alterations, leading to the inactivation of 
tumor suppressor genes (TSG) such as p14ARF, p16INK4a or p53, are needed. TSGs 
usually serve as a “gatekeepers” of cellular proliferation, and inactivation of TSG can 
result in the continuous replication of cells with DNA mutations and damage and further 
changes in the expression and function of additional genes, leading to further increases in 
malignant behavior. The losses of TSGs occur from chromosomal mutation, deletion or 
epigenetic changes such as methylation. The relatively high frequency of chromosomal 
losses in SCCHN compared to allelic gains highlights the the important role for loss of 
TSGs in carcinogenesis and tumor progression (Gollin, 2001).   
 
        The genetic or epigenetic changes in SCCHN can lead to altered activation of 
several signaling and transcription factor pathways that in turn regulate many of the 
several hundred genes and proteins altered in cancer. These common pathways may 
provide an insight to the tumor biology and may provide useful markers for molecular 
diagnosis and targets for therapy. The signaling pathways that have been implicated in 
the development of SCCHN are briefly reviewed in the following sections and are 
summarized in Figure 1.3.  In the following sections, several important molecules in 
SCCHN tumorigenesis are briefly reviewed in addition to their potential utility as 
biomarkers and/or targets for therapy.  
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Figure 1.3 Summary of the major signaling pathways involved in the development 
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1.2.1 Disruption of Mitogenic Signaling Pathways in SCCHN and Current Roles in 
Targeted Therapy 
 
1.2.1.1 EGFR   
        The EGF receptor (EGFR), also known as ErbB1 and HER1, is a receptor tyrosine 
kinase (RTK) belonging to the EGFR RTK family, which also includes ErB2 (also 
known as HER2), ErbB3 and ErbB4. Activation of the 170kD transmembrane 
glycoprotein receptor by binding of its ligands including EGF and TGF-α, etc, can lead to 
activation of many intracellular signaling cascades, including MAPK, signal transducer 
and activator of transcription (STATs) and Akt anti-apoptotic kinases pathways which in 
turn lcontributes to cell survival, proliferation, invasion, cell motility, angiogenesis & 
tumorigenesis (Ang et al., 2002; Robinson et al., 2000;Kim et al., 2008).  
        Over-expression of the EGFR protein is frequently (80-100%) observed in tumor 
specimens from SCCHN patients.  This over expression of EGFR is often accompanied 
by the over expression of one of its ligand, such as TGF-α (Grandis et al., 
1998;Dassonville et al., 1993). Over-expression of TGF-α has been found to occur early 
in carcinogenesis as it has been detected in mild dysplasia, with no further increases in 
advanced dysplasia or carcinoma. In contrast, EGFR over expression increases 
progressively with increasing degree of dysplasia and is markedly elevated in many fully 
transformed SCCHNs (Shin et al., 1994b).  
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        However, the mechanisms of EGFR over-expression are still unclear. Somatic 
mutations in EGFR in SCCHN are less common than in lung adenocarcinomas (Lee et al., 
2005), and gene amplification of EGFR is only detected as many as 15% of tumors 
(Temam et al., 2007).  EGFR vIII, a constitutively activated EGFR variant resulting from 
truncation of the extracellular domain, has been found infrequently in SCCHN (Zhu et al., 
2003; Kim et al., 2008). Sustained autocrine stimulation may be responsible for the 
activation of EGFR in SCCHN since over expression of EGFR is often accompanied with 
over expression of its ligand, TGF-α expression, and this association is often correlated 
with decreased disease-specific survival (Grandis and Tweardy, 1993). 
 
        High expression levels of EGFR correlates with a more advanced stage of the 
disease, a poor prognosis and worse response to chemotherapy (Rubin et al., 1998; 
Temam et al., 2007). Multiple Phase II and III clinical trials have demonstrated the 
therapeutic importance of targeting EGFR. Therapeutic approaches to target EGFR 
signaling include anti-EGFR monoclonal antibodies (mAbs) or small molecule tyrosine 
kinase inhibitors (TKIs). TKIs are administered as oral pills and convenient for outpatient 
treatment. MAbs can only be administered parentally but are more specific than TKI in 
target inhibition.  
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        Cetuximab, a monoclonal antibody to EGFR’s extra cellular domain, is currently the 
only molecular targeted agent approved by FDA based on the phase III clinical trial in 
newly diagnosed SCCHN comparing cetuximab plus radiation versus radiation 
alone(Bonner et al., 2006;Bonner et al., 2010). The response rate (RR) of single agent 
cetuximab in SCCHN patients who had failed treatment with cisplatin was 13% 
(Vermorken et al., 2007),  however, the addition of cetuximab to front-line platinum-
containing chemotherapy did not lead to either improved OS (overall survival) or 
DFS(disease –free survival ) (Burtness et al., 2005;Vermorken et al., 2007). The 
benefical effects of cetuximab plus chemotherapy in SCCHN were not confirmed until 
the Extreme Phase III trial, which randomized 442 recurrent/metastatic & chemotherapy 
naive patients to first-line PF (cisplatin & 5-fluorouracil) +/- cetuximab treatment 
(Vermorken et al., 2008). In this study, both PFS and OS were improved from 3.3 to 5.6 
and 7.4 to 10.1 months respectively. The result shows cetuximab is active in PF but not 
carboplatin-based chemotherapy and does not impair the tolerability of standard 
chemotherapy.  
 
        Gefitinib and erlotinib are two of the most widely used oral EGFR TKI clinically. 
As single agent treatment in recurrent and metastatic SCCHN, patients receiving gefitinib 
at higher dose (500 mg/m2) had higher RR (10.6 %) than those (1.4%) at lower dose (250 
mg/m2). (Cohen et al., 2005;Cohen et al., 2003). However, the IMEX (iressa versus 
methotraxate) study failed to demonstrate a survival advantage in single agent gefitinib  
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 (250 mg/m2 or 500 mg/m2) versus methotraxate (Stewart et al., 2009). The overall RR 
in erlotinib in the first- or second-line setting in SCCHN was 4.3% (with PFS 9 weeks 
and OS 6 months) (Soulieres et al., 2004). Two Phase II studies using either gefitinib or 
erlotinib plus chemotherapy as front-line treatment in recurrent/metastatic patients 
showed RR from 67-75%, and OS around 11 months (Belon J, 2010; Kim ES, 2010), 
suggesting a benefit to the addition of the agents to chemotherapy.  These observations 
are awaiting further confirmation in randomized phase III trials.     
 
        In summary, the response rates for single agent cetuximab or EGFR TKI usage in 
SCCHN are generally low. However, cetuximab has additive or synergistic effects when 
used in combination with systemic chemotherapy or radiation. The benefits of treatment 
with EGFR TKIs are still under investigation. Targeting EGFR has shown some anti-
tumor effects in SCCHN, however, only a minority of patients benefit from the treatment. 
High levels of EGFR tumor expression is associated with poor prognosis, but does not 
correlate with tumor response to EGFR-targeted therapy (Kies M, 2007).  
  
1.2.1.2 HER2/neu 
         The HER2/neu protooncogene is also encodes a transmembrane protein with 
protein kinase activity, and the HER2 gene product (also known as c-erbB-2) has 
extensive structural  
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 homology to EGFR and is over expressed in many solid tumors, including breast, lung, 
ovarian, and gastric cancers. In all of these sites, HER2 over expression has been 
identified as a negative prognostic factor. However, the results of HER2 expression in 
SCCHN are conflicting. The expression of HER2 in SCCHN ranges from <10% to 70% 
in some large series (Khademi et al., 2002;Akamatsu et al., 2003;Craven et al., 1992). In 
one study, the expression of HER is negative in normal oral mucosa and increased from 
dysplastic to malignant oral squamous cell carcinoma, indicating a dynamic change in the 
development of SCCHN (Fong et al., 2008). Some studies have shown that HER2  
expression correlates with decreased overall survival and can serve as a poor prognostic 
factor in SCCHN (Chen et al., 2003);  however, some other studies report a lack of 
correlation of HER2 expression with tumor grade, lymph node metastases and survival 
(Giatromanolaki et al., 2000; Khan et al., 2002).  
 
        Trastuzumab (Herceptin) is a humanized monoclonal antibody targeting the 
extracellular domain of HER-2. In breast cancer patients over expressing HER-2, it has 
shown significant anti-cancer activity (Pegram et al., 1998).  For cancers in the head and 
neck region, only a small subset of salivary ductal carcinomas have been reported to 
respond to trastuzumab therapy (Prat et al., 2008; Nabili et al., 2007). The effect of 
trastuzamab in the treatment of SCCHN has not been reported yet.  
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        Several studies have shown that the presence of HER-2 overexpression may 
contribute to the resistance of cancer cells to EGFR targeting therapy, providing a 
rationale for combination therapy with EGFR and HER-2 inhibition (Christensen et al., 
2001). HER-2 overexpression ahas also been shown to reduce the EGFR internalization 
rate and thereby results in an increase in the overall level of activated EGFR (Hendriks et 
al., 2003). Several studies have shown that the combination of Herceptin with anti-EGFR 
treatment can overcome the EGFR resistance. In SCCHN, tumor growth inhibition is also 
observed when gefitinib and pertuzumab (targeting HER-2 heterodimerization) or 
trastuzumab are combined in vitro (Erjala et al., 2006;Kondo et al., 2008). Since the 
levels of HER-2 over expression in SCCHN tumors vary in different studies and no 
synergistic effects have been observed in the combination anti-HER-2 treatment and anti-
EGFR treatment, more preclinical and clinical trials to confirm whether this type of 
combination treatment is of clinical benefit to SCCHN patients.  
 
 
1.2.1.3  Src kinase  
 
        Although EGFR targeted therapy has shown some anti-tumor effects clinically, only 
a minority of patients benefit from the treatment. Therefore, many research efforts have 
been  
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focused on the identification of  strategies to overcome the resistance of EGFR targeted 
therapy. Another emerging target for cancer therapy is the non-receptor kinase, src, a 
downstream molecule in the EGFR signaling pathway. Elevated c-src activity and/or its 
protein level has been reported in many cancers, including SCCHN (Xi et al., 2003). C-
src over expression in SCCHN promotes invasion and tumor growth. Constitutive 
activation of src may result in resistance to EGFR inhibitors, and thus EGFRi resistance 
might be overcome by combined inhibition of both targets:  src and EGFR. In vitro, 
combined treatment with the c-src inhibitor AZD0530 and gefitinib resulted in greater 
inhibition of SCCHN cell growth and invasion compared with either agent alone 
(Koppikar et al., 2008). However, in an in vivo study performed in mice, sustained src 
inhibition can lead to activation of STAT3 which may counteract its anti-tumor effects 
(Sen et al., 2009).   
 
 
1.2.2 Disruption of Cell Cycle Control in SCCHN and Its Impact on Targeted 
Therapy 
        In contrast to the over expression of genes that “turn on” or promote cell 
proliferation, the decreased inhibion of cell growth, which occurs commonly through the 
loss of tumor suppressor genes can also contribute to the tumorigenesis of SCCHN 
(Hanahan and Weinberg, 2000). Many tumor suppressor genes regulating the cell cycle  
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and other cellular processes are lost in SCCHN tumor development and progression 
including cyclin D1, p16, p53, etc.  
 
1.2.2.1 p16, CDK 4/6-Cyclin D1 and RB   
        The p16 pathway regulates cell-cycle entry and progression at the G1/S transition. 
(Figure 1.4) (Chiocca, 2002) as it is a potent inhibitor of the cyclin-dependent kinases 4 
and 6 (CDK4/6) –cyclin D complex. This complex increases the phosphorylation of the 
retinoblastoma gene product, pRB,  leading to the release of the transcription factor E2F, 
which mediates the functions of many cellular proteins leading to progression through 
G1/S. Therefore, the inactivation of p16, or overexpression of cyclin D1, increases 
CDK4/6 activity and promotes cell proliferation.  
 
 
 
 
 
 
Figure 1.4  The p16 pathway.  
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        The cyclin D1 gene is located on chromosome 11q13, the amplification of which is 
one of the most common cytogenetic alterations seen in carcinoma in situ lesions through 
SCCHNs (Gollin, 2001). Amplification and over expression of cyclin D1 has been 
described in up to 40% of cases of oral early premalignant lesions, including oral 
squamous dysplasia, or mild dysplasia (Rousseau et al., 2001).  In tumors, this genetic 
alteration is seen in 30–60% of HNSCC cases and has been correlated with tumor grade, 
recurrence, an increased lymph node metastases and poor prognosis (Perez-Ordonez et al., 
2006).  
 
        The tumor suppressor genes, p14 and p16,  are both encoded by CDKN2A gene 
through use of alternative first exons. CDKN2A gene is located on chromosome 9p21 
and loss of heterozygosity (LOH) of 9p21 has been proposed as an early event and is seen 
in 30% of the cases of squamous hyperplasia of the upper aerodigestive track mucosa. 
The loss of the chromosomal region 9p21 is found in 70–80% of all SCCHN cases, 
making it the most common genetic alteration (Van der et al., 1994).  Re-expression of 
the wild type p16 protein in SCCHN cells, in turn, leads to significant anti-tumor effects 
both in vitro and in animal models, indicating the importance of loss of p16 expression 
/function in SCCHN tumorigenesis (Liggett, Jr. et al., 1996; Rocco et al., 1998).   
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        Since the loss of p16 expression in dysplastic lesions of the oral mucosa is 
associated with an increased risk of progression SCCHN, the presence of 9p loss by LOH 
analysis is currently being used as a selection criteria for the chemopreventive treatment 
of patients with oral dysplasia with erlotinib in an NCI sponsored (EPOC trial).   
 
1.2.2.2  p14, MDM2 and p53  
        The major function of tumor suppressor gene p14ARF is to neutralize MDM2, an 
inhibitor of p53. Thus it subsequently blocks the association of p53 and MDM2 and leads 
to p53 stabilization and activation. Loss of p14 results in indirect inhibition of p53 
function. p53 is critically important  for suppressing aberrant cell proliferation through 
inhibition of cell cycle progression or induction of apoptosis (Gasco et al., 2002).  
        In a high proportion of cancers, p53 function is compromised without p53 mutation. 
Mechanisms include viral oncoproteins, loss of p14, increased expression of mdm-2, etc. 
This observation has taken on greater significance now that SCCHN of the tonsil and 
tongue base have been found to be strongly associated HPV infection (D’Souza et al., 
2007; Fakhry et al., 2008), The E6 and E7 proteins encoded by high risk HPV types 16 
and 18 bind to and induce the degradation of p53 and pRB respectively. E7 is found to be 
the major transforming oncogene during the early stage of carcinogenesis of SCCHN as 
compared to E6, which appears to function at later stage (Chung and Gillison, 2009). The 
loss of p14 has been reported in several human cancers, particularly those with wild-type  
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p53 (Vogelstein et al., 2000). In SCCHN tumors, inactivation of p14 has been reported to 
occur in 26.5% of cases (Shintani et al., 2001).    
 
       Mutation of the p53 gene is the most common genetic change in human cancer 
(Farnebo et al., 2010), and is estimated to occur in 50% of all cancers. P53 mutations are 
most often missense mutations that adversely impact its DNA binding function and, 
therefore its potential to transactivation of genes upregulated by the wild-type protein 
(Sigal and Rotter, 2000).  The proportion of missense mutations in p53 is higher than that 
seen in other tumor suppressor genes, indicating that expression of p53 mutants may 
possess additional functions and can confer selective advantags over wild-type p53 
(Hussain and Harris, 2000). In SCCHN, p53 is found inactivated or mutated in 50-80% of 
patients’ tumors (Shin et al., 1994a;Balz et al., 2003). Although some reports have shown 
that these mutations can be identified as early as dysplasia, other studies have found that 
p53 mutation may be a late event in tumor evolution (Boyle et al., 1993).   
        Identification of p53 mutation is of prognostic value in SCCHN patients. Patients 
with a p53 mutation were associated with reduced post-op survival and less chance to 
responding to neoadjuvant chemotherapy (Poeta et al., 2007; Temam et al., 2000). As a 
result of the high incidence of p53 mutations in SCCHN, several clinical trials targeting 
p53 have been undertaken (Khuri et al., 2000; Clayman et al, 1998). However, treatment  
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with single agent ONYX-015 , an engineered adenovirus that does not express E1B 
protein, only has marginal effect in SCCHN patients.     
1.2.3 VEGF   
        Overexpression of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-
8) have been reported in SCCHN (Howell and Grandis, 2005). VEGF is over expressed 
in SCCHN tumor expression and this overexpression is correlated with poor prognosis in 
SCCHN patients (Mineta et al., 2000). It has been shown that VEGF is upregulated by 
EGFR activation and confers resistance to anti-EGFR therapy (Charoenrat et al., 2000). 
In addition, combination treatment with bevacizumab, a monoclonal antibody to VEGF, 
and chemotherapy has been also shown more active than chemotherapy alone in many 
cancers types (Hurwitz et al., 2004).  
 
        Based on the pre-clinical/ clinical observations, several clinical trials using 
combination anti-VEGFR and anti-EGFR therapy or chemotherapy in SCCHN are under 
investigation for patients with SCCHN.    
 
1.2.4 Conclusion  
Over the preceeding decades, surgery, radiation and chemotherapy have been the major 
modalities used for primary SCCHN treatment,. In patients with recurrent and/or  
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metastatic disease systemic chemotherapy plays a more prominent role.  However, 
treatment in this setting has been characterized by limited survival benefit and significant 
toxicity. This is true even with more contemporary combination therapy with taxanes, 
such as cisplatin and 5-FU (PF). The advent of molecularly targeted agents has brought 
more hope for SCCHN patients.  For exmple in the Extreme trial, improvements in major 
response rate (RR) overall survival (OS) & progression free survial (PFS) were seen with 
the addition of cetuximab, an EGFR monoclonal, antibody(mAb).to classical PF.   
 
        In contrast, the current results from EGFR-specific tyrosine kinase inhibitors (TKI) 
have been disappointing, as only a small number of patients benefit from EGFR targeting 
therapy. High costs of mAbs and the identification of predictive factors have become 
important issues to explore.  On the other hand, many efforts have been spent to find 
ways to overcome the resistance to EGFR targeting therapy including HER2, VEGFR, 
src, etc. With the explosive accumulation of knowledge in understanding the 
carcinogensis of SCCHN, we expect to see more and more SCCHN patients will benefit 
from the risk factor-stratifiedm as well as specific targeted therapeutic approaches.     
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1.3 The Role of Inflammation, Inflammatory Cytokines IL-6 and Casein Kinase 2 in 
SCCHN 
        Inflammation is a protective reaction to tissue injury, irritation, or disease, and is an 
important part of innate immunity. It has been noted that many chronic inflammatory 
conditions increase the incidence of cancer development (Gonda et al., 2009).  Examples 
of this include ulcerative colitis and colon cancer; chronic hepatitis/cirrhosis and 
hepatocellular carcinoma; HPV infection and cervical cancer; and Helicobacter pylori 
infection and gastric carcinoma. (Hagemann et al., 2007). In SCCHN carcinogenesis, 
many important and commonly cited risk factors such as smoking, betel nut chewing, 
poor oral hygiene, and HPV infections often contribute to increased proinflammatory 
cytokine expression and aberrant signaling through inflammatory pathways (Allen et al., 
2007b;Molinolo et al., 2009).   
        The growth of SCCHN is generally associated with an inflammatory component, 
however, many inflammatory cytokines such as interferons, tumor necrosis factors, 
interleukin-6 have been found to be largely responsible for suppressing proliferation of 
normal epithelial cells in association with inflammation (Grohmann and Puccetti, 2002; 
Hernberg et al., 2003;Grant and Begley, 1999). Therefore in the presence of a 
background, inflammation SCCHN cancer cells must develop molecular strategies to 
escape anti-tumor immune responses (Lu and Kerbel, 1994). Furthermore, the presence 
of cells involved in innate immunity, including macrophages, can contribute to malignant 
progression  
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via the production of proinflammatory mediators such as tumor necrosis factor (TNF)-α 
and interleukin (IL)-6 (Greten et al., 2004; Maeda et al., 2003), therefore, attention has 
been focused on the role of NF-κB and its upstream activator, IKKβ, in the link between 
inflammation and cancer. In this section, we will review the current studies regarding 
NF-κB in SCCHN and then explore the roles of major cytokines involved in the 
tumorigenesis and tumor progression of SCCHN.   
 
1.3.1 Aberrant Activation of the NF-kB Pathways in SCCHN 
        NF-kB is a transcription factor found to play an important role in the expression of 
genes involved in inflammation and immune responses. The signaling pathway 
controlling the activity of NF-kB is summarized in Figure 1.5. NF-kB acts as a 
heterodimer and the most common form of this is p50/RelA. In the resting state, NF-kB 
is inactive and retained in cytoplasm by binding to its inhibitory proteins including IκBα. 
In response to inflammatory signals, IκB kinase (IKK) complexes are activated leading to 
phosphorylation of IκBα, and the subsequent release of NF-kB with translocation to 
nucleus.  This translocation enables NF-kB to activate the transcription of its target genes 
including cyclin D1, c-myc, XIAP, Bcl-xL, Bcl-2, VEGF, IL-8, COX2, and matrix 
metalloproteinases (MMP) (Chen and Castranova, 2007).     
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Figure 1.5 The mechanisms of NF-kB activation and the signaling pathway  
        NF-kB is induced by nicotine and other carcinogens contained in tobacco and betel 
nut, two of the most important carcinogenic agents that promote development of SCCHN 
(Zhang et al., 2006; Anto et al., 2002).  Several studies have shown that NF-kB is 
aberrantly activated in human SCCHN cell lines (Ondrey et al., 1999;Arun et al., 2009). 
Increased nuclear staining of the phosphoactivated form of p65 has been shown to occur 
in premalignant dysplastic lesions and ~85% of SCCHN specimens, and correlated with  
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decreased survival, indicating that it is an early event and associated with tumor 
development  (Zhang et al., 2005; Arun et al., 2009). Since NF-kB was found to be 
constitutively activated in SCCHN cell lines and tumors, several mechanisms 
contributing the activation have been proposed such as genetic alterations already present 
in the epithelium and autocrine or paracrine activation by cytokines from tumors 
themselves or microenvironment. Kinases/ Cytokines/ growth factors that phosphorylate 
IκB and can lead to activation of NF-kB include IKKs (IκB kinases), CK2 kinase , IL-1α , 
tumor necrotic factor-α (TNF),  and EGF  (Wolf et al., 2001; Helms et al., 2001; Yu et al., 
2006; Biswas et al., 2000). Interfering with NFκB function in SCCHN results in down 
regulation of many cytokines and chemokines such as IL-2, IL-5,IL-8, IL-6, IL-10, IL-12, 
IL-13, IL-17, GM-CSF, and G-CSF as well as a remarkable reduction in cell survival and 
tumor growth (Molinolo et al., 2009). In addition, aberrant NFκB activation leads to 
activation of STAT3 independent of EGFR (Squarize et al., 2006), which may contribue 
to EGFR inhibitor resistance. 
 
        Recently, NF-kB and its upstream activating signals have been proposed as a 
potential target in cancer treatment.  In SCCHN, bortezomib, an inhibitor of proteasome 
and I-kB degradation, has shown to have anti-tumor effects in preclinical and phase I 
studies (Roccaro et al., 2006). However, the anti-tumor effects of bortezomib are limited 
by the achievable dose within tumors and toxicity. In addition, many studies found that  
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NF-kB also has tumor suppressor activity in several specific cell types including mouse 
embryonic fibroblasts (Chen et al., 2006), human skin cancer models (Seitz et al., 1998) 
and mouse liver cancer models (Chen and Castranova, 2007). These findings suggest that 
caution is needed in inhibiting NF-kB pathways as a broad strategy in cancer treatment.    
 
1.3.2 The Role of IL-6 in the Pathogenesis and Tumor Progression of SCCHN  
        Given that NF-kB activates different proinflammatory cytokines and chemokines 
and is commonly activated in many types of cancers including SCCHN, it is not 
surprising that the expression of many cytokines and growth factors including IL-6, IL-8, 
and VEGF-A, is upregulated in SCCHN (Pries et al., 2006).  
        IL-6 is a major mediator of inflammatory response and its expression is under NF-
kB’s control. It is involved in embryonic development, organogenesis, differentiation as 
well as tumor growth (Yoshida et al., 1996). IL-6 is upregulated in many epithelial cancer 
cells such as those breast and prostate (Sasser et al., 2007; Wegiel et al., 2008). In 
SCCHN patients, IL-6 can be detected in the serum and saliva as well as the tumors of 
patients. In a small prospective clinical study, the plasma level of IL-6 was found to 
correlate with the response of SCCN tumors to treatment (Allen et al., 2007a), indicating 
its potential role in SCCHN tumor progression. Results from a large (N=444) prospective 
study in SCCHN patients, indicate that IL-6 expression could be a valuable biomarker for 
predicting recurrence and overall survival among HNSCC patients (Duffy et al., 2008).  
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        There are 3 members of the IL-6 subfamily (or the gp130 sharing cytokine family); 
IL-6, leukemia inhibitory factor (LIF) and oncostatin M (OSM) (Auernhammer and 
Melmed, 2000; Gadient and Patterson, 1999;Grenier et al., 1999;Klausen et al., 2000). 
These factors are released at the sites of injury by activated monocytes, neutrophils, mast 
cells, dendritic cells and lymphocytes. Through a paracrine loop, these factors can act on  
adjacent endothelial, epithelial and stromal cells. The receptors for IL-6 subfamilty 
cytokines include non-signaling α-receptors (e.g. IL-6Rα, IL-11Rα, and CNTFRα ) and  
signal transducing receptors (e.g. gp130, LIFR, and OSMR) (Heinrich et al., 2003). The 
latter associate with JAKs and become tyrosine phosphorylated in response to cytokine 
stimulation. Each of the IL-6-type cytokines is recognized by a specific receptor subunit 
in combination with the shared gp130.  
 
        The canonical signaling pathways following IL-6 treatment involve (1) JAK-STAT 
(2) PI3K-AKT and (3) Ras-Raf-MAPK, which are summarized in Figure 1.6 (Heinrich et 
al., 2003). In addition to MAPK cascades, IL-6 also activates the stress-activated 
members of the MAPK family: p38 and JNK (Bode et al., 2001; Zauberman et al., 1999) 
through JAK phosphorylation, which creates docking sites for STAT and adaptor proteins. 
Following the signaling events, genes involved in acute phase reaction and inflammation 
are activated.     
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        Since decreasing IL-6 in serum is associated with response to therapy, while 
increasing its level is related to cancer progression and recurrence, many efforts have 
been made to better determine the role of IL-6 in tumor progression. In addition to the 
contribution to proliferation and invasiveness of SCCHN cancer cells through the JAK-
STAT pathway, IL-6 treatment can increase HGF and VEGF expression by SCCHN cells 
(Kanazawa et al., 2007). A recent study using tocilizumab, a monoclonal antibody against 
IL-6, reduced tumor growth and angiogenesis in of SCCHN tumor cells in mice (Shinriki 
et al., 2009), supporting the concept that IL-6 is important for SCCHN progression.  
 
        Although the link between IL-6 and cancer is strong from clinical observations, a 
discrepancy between in vitro and in vivo studies remains.  Several in vitro studies have 
shown that IL-6 treatment can inhibit SCCHN growth, whereas, IL-6 appears to stimulate 
in vivo tumor growth (Knupfer and Preiss, 2007).  A recent study showed RasG12V 
induced IL-6 expression is required for tumor growth of human kidney cells in vivo.  
However, another study using primary human fibroblasts IL-6 treatment results in 
senescence (Ancrile et al., 2007; Kuilman et al., 2008). One potential clue to solve this 
discrepancy may be the presence or absence of the CDK inhibitor p15INK4B. Using 
MCF10A cells which have deletion of chromosome 9p21, that encodes the INK4-ARF 
(Iliopoulos et al., 2009), or human kidney cells over expressing SV40 T antigen, which  
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inactivates the ARF-p53 and INK/Rb (Ancrile et al., 2007), researchers observe a tumor 
promoting role for IL-6; while in the study using human fibroblasts, in which the locus is 
intact, IL-6 induced anti-proliferation effect is observed.   These studies indicate that of 
the cellular response to IL-6 response depends at least in part on the status of the 
INK4/ARF locus (Houk et al., 2009). Since deletion at chromosome 9p21 is commonly 
observed in oral premalignant lesions and SCCHN, this may strengthen the oncogenic 
role of IL-6 in the tumor progression in SCCHN if the concept can be experimentally 
validated.  
1.3.3 The Role of Casein Kinase 2 (CK2) in SCCHN  
1.3.3.1 Overview of the Structure of CK2 
        Casein kinase 2 (CK2) was first discovered in 1954 by Burnett and Kennedy (Pinna, 
1994; Burnett and Kennedy, 1954): 
“An enzyme capable to catalyzing the transfer of phosphate from ATP to protein has 
been discovered in the rat liver mitochondria. Of a number of proteins tested, only casein 
is phosphorylated at an appreciable rate…”   
 
         Based on this ability to phosphorylate β-casein at its discovery this protein was 
initially referred to as casein kinase 2 (CK2), which represents a distinct protein family 
from CK1 serine/threonine kinase superfmaily in terms of the structure, substrates and 
phosphorylation consensus motifs. Fifty-six years after its first description, there have 
been over 2000 publications describing its activity and biological functions and more 
than 300 substrates for this kinase have been identified (Cozza et al., 2010; Meggio and 
Pinna, 2003;Litchfield, 2003).  
 33
Introduction 
  
         There are three different subunits that comprise the CK2 hetero-tetrameric complex: 
α (MW:41KD), α’ (MW: 38KD), and β (MW: 28KD). Two catalytic ( αα, α’α’, or αα’) 
and two β regulatory subunits make a complete CK2 heterotetramer (ααββ, α’α’ββ, or 
αα’ββ) (Pinna, 2002). The sequence similarity between the catalytic subunit of CK2, α 
and α’, is about 75% (Cozza et al., 2010). The most important primary structural 
differences are in the C-terminal region, however, these do not significantly impact the 
kinase activities (Cozza et al., 2010).  CK2α’ is highly expressed in mouse testis and 
brain. In testis, CK2α’ protects developing spermatocytes from apoptosis while CK2 α’ 
deficiency leads to oligospermia and abnormal development of the sperm head (Seldin et 
al., 2008). The deletion of CK2α’ (CK2α’ -/-) is well tolerated but the males are infertile. 
(Xu et al., 1999).  Mice lacking CK2α subunit (CK2α -/-) die in mid-gestation, with 
structural defects in the heart and neural tube (Lou et al., 2008), indicating that CK2α and 
CK2α’ are not redundant. The CK2β subunit is well known to enhance the stability and 
the catalytic activity of CK2 and function as an acceptor site for intramolecular 
autophosphorylation (Ackerman et al., 1990). However, as many cellular proteins such as 
p53, DNA topoisomerase II, FGF-2, and eIF2β identified in recent studies directly 
interact with CK2β, this subunit is believed to provide a docking site or a recruitment 
surface for substrates or potential regulatory proteins (Filhol et al., 1992; Bojanowski et 
al., 1993; Bonnet et al., 1996; Poletto et al., 2008). Of note, deletion of the CK2β subunit 
in mice is also embryonally lethal (Buchou et al., 2003). All of these studies indicate that 
CK2 plays a in cell survival.  
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1.3.3.2 Major Cellular Functions of CK2 
        Protein kinase CK2 is a ubiquitously expressed  and highly conserved serine-
threonine kinase, which is localized in the cell nucleus and cytoplasm. It is intimately 
involved in the control of cell growth, proliferation and differentiation through the 
regulation of DNA transcription, protein translation, and stability (Guerra and Issinger, 
1999; Ahmed, 1994; Zhu et al., 2010; Poletto et al., 2008; Kato, Jr. et al., 2003). To date, 
many important CK2 substrates are nuclear proteins such as RNA polymerase I and II, 
DNA topoisomerase I and II, nucleolin, and nucleolar proteins B23 as well as the cellular 
oncoproteins myc, myb and jun (Pinna, 1990; Issinger, 1993; Bousset et al., 1993; Tawfic 
et al., 1999), which may emphasizes its role in DNA replication and cell proliferation. Of 
note, the ubiquitin/proteasome degradation of many cellular proteins such as IκBα and 
PML are mediated through CK2 phopshorylation (Scaglioni et al., 2008; Poletto et al., 
2008; Kato, Jr. et al., 2003). Since most of the CK2 substrates identified so far are linked 
to fundamental cellular processes, it is not surprising that attempts to knock out the 
catalytic subunit of CK2 (CK2α) in mice resulted in embryonic death (Lou et al., 2008) 
and aberrant activation of CK2 function in the cell results in malignant transformation 
(Faust et al., 1996).  
 
        In addition to cell survival, dysregulation of CK2 is also involved many 
inflammatory or viral infectious disease such as glomerulonephritis and SLE (systemic 
lupus erythematosus) (Yamada et al., 2005). Many proteins involved in the signaling 
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 pathways implicated in inflammation and viral infection have been shown to be 
regulated by interaction with CK2. For example, CK2 phosphorylates the HIV-1 reverse 
transcriptase (Rev) in a CK2β dependent mechanism (Marin et al., 2000). Viral proteins 
such as E7 from HPV (human papilloma virus), EB2 from EBV (Epstein-Barr virus), and 
many others from HSV( herpes simplx virus) are CK2 substrates (Chien et al., 2000; 
Massimi and Banks, 2000; Medina-Palazon et al., 2007;Bryant et al., 2000).   
 
  CK2 activity has also been linked to the pathogenesis of atherosclerotic disease as 
well as hypoxia signaling  (Guerra and Issinger, 2008; Sarno and Pinna, 2008). Studies of 
MCP-1 (monocyte chemoattractant protein), a marker of macrophage activation, have 
shown that CK2 is in the pathway of interferon-γ signaling impacts macrophage function 
during atherosclerosis (Harvey et al., 2007). Studies reveal that CK2 activity is increased 
under hypoxic conditions, enhancing the activity of HIF-1α (Hubert et al., 2006). Of note, 
several studies have shown that CK2 is involved in retinal neovascularization (Kramerov 
et al., 2006; Ljubimov et al., 2004), implicating this kinase in angiogenesis. 
 
        In addition the to its intracellular functions, CK2 can also be found on the external to 
cells where it can phosphorylates extracellular proteins or the external domains of 
proteins (Rodriguez et al., 2008). Substrates that have been identified for this ectokinase 
function of CK2 include vitronectin, a protein that regulates the cell adhesions 
(Stepanova et al., 2002;Seger et al., 2001); collagen XVII, a receptor whose  
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phoshorylation inhibits its degradation by metaloproteases (Zimina et al., 2007); and the 
C9 complement protein that controls cell lysis (Bohana-Kashtan et al., 2005). The major 
cellular functions of  CK2 are summarized in Table 1.  
 
1.3.3.3 Regulation of CK2 and CK2-Involved Pathways 
        While CK2 is constitutively active, in vitro, studies with intact cells have shown that 
CK2 activity can be modulated by treatment with  serum (Orlandini et al., 1998; Carroll 
and Marshak, 1989), UV induced DNA damage (Kato, Jr. et al., 2003; Kapoor and 
Lozano, 1998; Keller et al., 2001), and growth factor or cytokine treatment (Ji et al., 
2009; Ackerman et al., 1990; Litchfield et al., 1994; Sommercorn et al., 1987; Klarlund 
and Czech, 1988; Litchfield, 2003). In the EGF signaling pathway, CK2α was shown to 
be a direct substrate of Erk2 at site T360/S362 (Ji et al., 2009). The CK2β subunit has 
also been reported to be phosphorylated in response to EGF treatment, with concomitant 
activation of CK2 kinase activity (Ackerman et al., 1990). The factors that can regulate 
the activity or the stability of CK2 are summarized in Table 2.  
 
 The NF-κB pathway is the most well studied pathway related to CK2. Within this  
pathway, CK2 can phosphorylate IKK2 and promote its activity and it has been proposed 
that this is a mechanism of abberant NF-κB activation in SCCHN (Yu et al., 2006). In 
addition, CK2 has been previously shown to phosphorylate multiple sites in the COOH-
terminal PEST domain of  IκBα as well as S529 of the Rel/p65 subunit (McElhinny et al.,  
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1996; Kato, Jr. et al., 2003; Wang and Baldwin, Jr., 1998; Wang et al., 2000). TGF-β 
treatment of normal mouse hepatocytes leads to decreased CK2 expression and activity, 
with enhances stability of IκB and decreased NF-κB activity(Cavin et al., 2003).     
 
       CK2 is also believed to have a role in the regulation of the Wnt signaling pathway as 
it can phosphorylate β-catenin in the armadillo repeat protein interaction domain (T393) 
thereby stabilizing its expression, and counteracting GSK3 activity(Seldin et al., 2005; 
Song et al., 2000; Song et al., 2003). This region is also important for β-catenin’s 
interaction with E-cadherin at cellular membrane and APC and axin in the cytoplasm and 
TCF/LEF transcription factors in the nucleus. 
 
1.3.3.4 The role of CK2 in Cancer Development and Progression  
        There is increasing evidence that CK2 is overexpressed in multiple forms of cancer 
such as prostate, colon and lung cancers (Ahmed, 1994; Munstermann et al., 1990; Ya-
Makin et al., 1994) and the level of expression is correlated with aggressive tumor 
behavior and poor prognosis in cancers (McCaffery et al., 1997; Landesman-Bollag et al., 
2001a; Charoenrat et al., 2004; Gapany et al., 1995). In SCCHN, CK2 expression and  
activity are both elevated in tumors as well as cell lines (Gapany et al., 1995).When 
compared with normal oropharyngeal mucosa, the CK2 activity in SCCHN tumors was  
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increased, suggesting its role in tumorigenesis (Faust et al., 1996). The activity of CK2 in 
tumors correlates with aggressive behavior and poor prognosis of patients with SCCHN 
(Gapany et al., 1995; Faust et al., 1996).   
 
        Evidence from studies in genetically engineered mice that over-express CK2 in the 
lymphocytic compartment or mammary gland and go on to develop malignant 
transformation of lymphocytes and  mammary glands emphasize the oncogenic role of 
CK2 (Seldin and Leder, 1995; Landesman-Bollag et al., 2001b).  In studies in prostate 
cancer, over expression of CK2 in PC3 cells prevents etoposide induced apoptosis , and 
decreased expression of CK2 mediated by anti-sense DNA leads to reduced viability of 
PC3-LN4 in vitro and cell death in vivo(Unger et al., 2004; Slaton et al., 2004). In 
addition, antisense to CK2α leads to the growth inhibition of squamous cell carcinoma 
cells, Ca9-22 (Faust et al., 2000).  Anti-sense to both CK2α and CK2α’ were required to 
enhance apoptosis in HeLa cells (Seeber et al., 2005). Interestingly, anti-sense CK2α  
only had marginal pro-apoptotic effect on benign BPH-1 or normal PrEC prostate cells 
(Slaton et al., 2004), which indicates a minimal effect on normal or benign tissues 
supporting its potential utility as an anti-cancer target. 
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1.3.3.5 Conclusion 
 There appears to be a strong correlation between inflammation and the development and 
progression of head and neck cancer , as oral inflammation often precedes the 
development of oral cancer and the serum levels of inflammatory cytokines correlate with 
a tumor’s response to treatment.  This suggests a model in which carcinogen exposure 
together with inflammatory cytokines create an environment that initates the mutation or 
deletion of tumor suppressor genes (such as 9p21 deletion), and activiation of oncogenes 
and also promotes the growth of these genetically altered cells.    
 
        While the ability to restore the function of defective genes may hold therapeutic 
potential, we have also learned that, as they progress, most SCCHN cancers may become 
addicted to, and therefore dependent on, the aberrant activation of multiple signaling 
pathways including EGFR, NF-κB, JAK/STAT, and Akt-mTOR.  In spite of the multi-
stage carcinogenesis and multiple signaling pathways involved, the development of 
cancers is not simply a summation of the effects. The functions of an oncoprotein are 
usually complex: while they may enhance proliferation, they may also activate 
senescence and anti-apoptotic pathways.  As a consequence, cancer cells may be more 
dependent on the activity of a specific oncogene than normal cells, a process called 
“oncogene addiction” (Weinstein, 2002). The phenomenon provides a rationale for 
modern targeted therapy.  
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Table 1 Summary of the major cellular functions of CK2  
 
Cellular Function of CK2 
Proliferation 
Anti-apoptosis  
Inflammation 
Viral infection 
Cell migration 
Angiogenesis  
Motility and Invasiveness  
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Table 2 Summary of the known factors that regulate the activity of CK2 and 
proteins known to stabilize CK2 or destabilized by CK2 
 
Factors that regulate CK2 activity References 
Serum  (Orlandini et al., 1998; 
Carroll and Marshak, 1989)
DNA Damage (e.g. UV )  (Kato, Jr. et al., 2003; 
Kapoor and Lozano, 1998; 
Keller et al., 2001), 
Growth factors: EGF, IGF, insulin-like growth factor  (Ji et al., 2009; Ackerman 
et al., 1990; Litchfield et 
al., 1994; Sommercorn et 
al., 1987; Klarlund and 
Czech, 1988) 
Cytokines: TGF-β, IL-6   (Litchfield, 2003) 
 
 
 
 
Proteins that are stabilized by CK2  activity References 
c-myc  (Channavajhala and 
Seldin, 2002) 
β-catenin  (Seldin et al., 2005; Song 
et al., 2000; Song et al., 
2003). 
  
 
 Proteins that are destabilized by CK2 activity References 
IκBα (Kato, Jr. et al., 2003) 
PML  (Scaglioni, et al. 2008) 
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1.4 The Role of Twist in Cancer Progression 
 
1.4.1 Brief Review of Helix-loop-helix (HLH) Family of Transcription Factors  
        Twist is a highly conserved protein belonging to basic helix-loop-helix (bHLH) 
transcription factor family. Studies from Xenopus laevis, Drosophila melanogaster and 
mice have shown convincingly that HLH family proteins play important roles in many 
developmental processes such as lineage commitment, differentiation (e.g. myogenesis, 
neurogenesis and hematopoiesis), heart / pancreatic development and sex determination 
(Bain et al., 1994; Lee et al., 1995; Porcher et al., 1996). In addition, they have also been 
demonstrated to regulate some important metabolic pathways such as phospholipid 
biosynthesis and phosphate uptake (Hoshizaki et al., 1990; Ambroziak and Henry, 1994).  
 
1.4.1.1 The bHLH Protein Structure  
       There are two important and high conserved regions in the bHLH protein family that 
enable these proteins to interact with DNA as well as other bHLH proteins: (1) a region 
containing basic residues that enhances binding to DNA and (2) an HLH domain, which 
facilitates protein-protein interaction with other bHLH family members to form homo- or 
heterodimers (Murre et al., 1994). HLH proteins that lack basic region lose the ability to 
bind DNA (Cabrera et al., 1994). The DNA binding site for bHLH proteins is known as 
the E box (CANNTG), which was originally identified as the immunoglobin heavy chain 
gene Enhancer (Church et al., 1985).  The E-box appears in promoter and enhancer  
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regions which regulate a large number of neuron-, muscle-, and pancreatic genes’ 
expression. However, the E-box is not sufficient for binding with specific HLH proteins. 
Either the nucleotides flanking the E-box or other factors such as dimerization choice 
play a crucial role for the biological specificity of these proteins.  
 
        In addition to the basic region, the loop and C-terminal helix also make contact with 
the major groove of DNA (Harrison and Aggarwal, 1990). The helical structure is 
important for dimerizatiing with other HLH protein family member (heterodimer) or 
itself (homodimer). The interaction between HLH proteins occurs between four helices, 
which help stabilize the dimer proteins in the absence of DNA (Ferre-D'Amare et al., 
1993). The activity of bHLH transcription factors is largely controlled by the 
dimerization of other partner proteins. For example, introducing the basic region of E12 
to MyoD preserves the DNA binding ability but inhibits myogenesis (Davis et al., 1990). 
For heterodimers, usually one partner stimulates transcription (positive regulator) and the 
other inhibits it (negative regulator). Some bHLH familty proteins such as Id (Inhibitor of 
differentiation) and emc, lack a basic region and they function as inhibitory regulator to 
other proteins since they still can dimerize with their dimer partner but forfeit their DNA 
biding ability and inactivate specific gene regulatory function (Williams and Ordahl, 
2000).  
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1.4.1.2 Classification of bHLH Protein Family  
        As shown in Table 3, the bHLH family is currently divided into 7 classes according 
to their dimerization capacities, DNA–binding specificities and tissue distribution 
(Thompson et al., 1994). Class I bHLH proteins are ubiquitously expressed and known as 
E proteins , which include E12, E47, HEB, E2-2 and daughterless. They can form either 
homo- or hetero-dimers (Murre et al., 1989). For example, daughterless protein, which is 
a Drosophila HLH protein, can form heterodimer with achaete-scute T4 and control sex 
determination (Cline, 1989).  
 
        Class II bHLH proteins are tissue-specific transcription factors, including MyoD, 
myogenin, NeuroD/BETA2, achaete-scute-T4 and Twist. With very few exceptions, they 
can not form homodimers and preferentially form heterodimers with E proteins (Massari 
and Murre, 2000). For example, MyoD and myogenin are muscle-specific HLH proteins, 
known as myogenic regulatory factors (MRFs), which can convert mesodermal cell lines 
C3H10T1/2 to myoblasts (Olson and Massey, 1979).  The heterodimers with E12 bind 
strongly with E2-box sites while the oligmers or homodimer of E12 or MyoD bind with 
low affinity (Murre et al., 1989). 
 
        Class III bHLH proteins are a group of proteins with an LZ (leucine zipper motif) 
adjacent to the HLH motif, including the Myc family, TFE3, and SREBP-1(Zhao et al., 
1993). 
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        Class IV includes proteins such as Mad, Max, Mxi1 that can dimerize each other or 
with the Myc proteins.  Class V bHLH proteins are negative regulators of Class I and II 
proteins. This group includes Id and emc, both of which lack a basic region and inhibit 
DNA binding ability through dimerization with Class I or II proteins (Benezra et al., 
1990).  Class VI bHLH proteins contain proline in their basic region and Class VII bHLH 
proteins have abHLH-PAS domain. This group includes the hypoxia-inducible factor 1α 
(HIF-1 α).  
 
The classification of bHLH proteins is summarized in Table 3. 
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Table 3 Classification of bHLH protein family  
 
 
Class I ubiquitously expressed E12,E47, HEB, E2-2, daughterless 
Class II tissue-specific  Tal1, Hen1, eHAND, dHAND, neurogenin, 
NeuroD/BETA2, MATH1, MyoD, myogenin,  
achaete-scute-T4 , Twist 
Class III containing LZ (leucine
zipper) motif 
c-Myc, TFE3, Mi,TFEB, SREBP-1, SREBP-2 
Class IV Mad, Max, Mxi1 
Class V lack of basic region;
transcription inhibitor
Id (Id1,Id2,Id3, & Id4) and emc
Class VI Containing proline in 
basic region
HES-1, HES-3, hairy,
Class VII Containing bHLH-PAS 
domain 
Trh, Sim, AHR, HIF-1
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1.4.1.3 The Potential Role of bHLH Proteins in Tumor Development  
        It is well established that E2A (or E) proteins (either E12 or its alternative spicing 
product, E47) are important regulators for B- and T- lymphocyte development (Zhuang et 
al., 1994; Bain et al., 1999). Knocking-out the expression of E2A in mice leada to 
abnormal T- cell development and rapid development of T-cell lymphomas (Bain et al., 
1997), suggesting E2A proteins can act as tumor supressors. However, E2A proteins are 
ubiquitously expressed in many tissues in addition to lymphocytes. In studies studying 
epithelial tissues or cell lines, E2A proteins were found to participate in the EMT process 
through repression of E-cadherin expression, thereby contributing to tumor progression 
(Perez-Moreno et al., 2001).   
The bHLH protein, E47 has been found to induce α-smooth muscle actin (α -SMA) 
expression in multiple cell systems (Peinado et al., 2007) and E47 phosphorylation by 
p38MAPK regulates its oligomerization and DNA binding ability (Lluis et al., 2005). 
During B cells development, E12 and E47 can be phosphorylated by cyclin dependent 
kinases (CDKs)(Chu and Kohtz, 2001). In lymphocyte differentiation, the degradation of 
E47 in under control of Notch-ERK-mediated phoshporylation (Nie et al., 2003).  
In spite of the active involvement of E47 in EMT, multi-drug resistance and tumor 
progression, the expression of E47 expression in human tumor samples has not been that 
well characterized.    In contrast, studies in the inhibitors of the E2A protein such as Id 
have been shown to be overexpressed in over 20 types of cancers such as breast, colon  
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and prostate cancers (Wong et al., 2004) and correlate with metastasis and poor prognosis 
(Perk et al., 2005). Id-1 has been shown in vitro, to regulate cell senescence, growth and 
survival (Ohtani et al., 2001; Swarbrick et al., 2005; Ling et al., 2003), suggesting an 
oncogenic role for this bHLH protein in tumor progression.  In pancreatic tumor 
specimens, Id-1 was associated with increased intra-tumor vascular density, indicateing 
that Id-1 could play a role in promoting angiogenesis (Lee et al., 2004). A later study 
using highly specific Id1 antibody reassessing their previous work on prostate, breast and 
bladder cancer showed only 1/30 prostate cancer samples,   10/45 poorly differentiated 
breast cancer samples and most transitional bladder carcinomas were positive for Id1 
(Perk et al., 2006). These results brought questions regarding the studies of Id1 
expression in human tumors and emphasize the importance of specific Id1 antibody in 
such studies.   
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1.4.2 Twist Gene, mRNA and Protein structure 
        The human Twist1 gene (GenBank Accession No. NM_000474) (Howard et al., 
1997) consists of two exons and one intron, encoding a 202 amino acid protein. 
(Figure1.7). There are two TATA boxes at -32 and -110 upstream of the encoding region 
and two poly-A sites within exon 2.  
  
Figure 1.7: Scheme of the human Twist1 gene structure  
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        The coding strand of Twist consists of 606 nucleotides with GC % 71.6%. GC 
content in the third positions of codons (GC3%) is 91.6%. In mammalian cells, GC-rich 
genes lead to increased steady-state mRNA levels and were expressed several fold to 
>100 fold more efficiently than their GC-poor counterparts (Kudla et al., 2006).  
 
        Twist protein belongs to the Class II bHLH protein family that consists of a group of 
tissue-specific transcription factors. Comparisons of the Twist protein sequences form 
different species (ranging from zebrafish, frog, chicken, rat, mouse to human), has led to 
the identification of several high conserved domains.   
 
        In addition to the basic loop (position 108-120) and the two helix domains ( at 
position 121-161) discussed above, four additional protein regions have been described in 
Twist (Singh and Gramolini, 2009):  
(1) NSEEE-motif (position 19-23): a highly conserved sequence domain at N-
terminus, of unknown function. 
(2) NLS1 domain ( RKRR; position 37-40): consensus motif for the nuclear 
localization signal  
(3) NLS2 domain (KRGKK, position 73-77)  
(4) WR-motif : another evoluationally conserved motif at the C-terminus(Castanon 
and Baylies, 2002). The WR motif is located 20 -55 amino acids C-terminal to the 
bHLH domain and its function is unclear. However, it might play role in  
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maintaining the stability of Twist mRNA or protein folding since a nonsense mutation 
before the WR motif can lead to mild presentation of Saethre–Chotzen syndrome, a 
human craniosynostosis disorder related to Twist mutation (Gripp et al., 2000).  
 
1.4.3 The Regulation of Twist Function  
 
        It has been reported that the epidermal growth factor (EGF), fibroblast growth factor, 
and interleukin-6 (IL-6) can increase Twist expression and the Twist-dependent EMT (Lo 
et al., 2007; Zuniga et al., 2002; Sullivan et al., 2009). Twist has been reported to regulate 
the transcription of STAT3, HIF-1 and NF-κB (Lo et al., 2007; Yang and Wu, 2008; 
Cheng et al., 2008b; Pham et al., 2007).  Twist has also been shown to rapidly activate or 
repress other genes upon growth factor or cytokine treatment (Hamamori et al., 1997; Lee 
et al., 1997), suggesting the importance of regulation at a post-translational level. 
However, the mechanisms of the post-translational regulation of Twist have not been 
clearly defined, but potential mechanisms include: (1) Twist phosphorylation by protein 
kinase A (PKA) and dephosphorylation by protein phosphatase 2A (PP2A); (2) 
regulation of Twist’s transcriptional activity through dimerization in which its binding 
parter determines whether there is transcriptional activation or repression ; and (3) 
Ubiquitin/proteasome mediated Twist degradation.    
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Studies of Twist mutations in patients with SCS have shown that Twist is phosphorylated 
by protein kinase PKA and dephosphorylated by PP2A) at T121/S123 (Firulli et al., 
2005), which in turn regulates the dimerization choice and differential control. In cancer 
cells, a study has shown that Twist can be phosphorylated by Akt at Ser 42 (Vichalkovski 
et al., 2010), which leads to inhibition of p53 function in response to DNA damage. 
Similar to other proteins, Twist is degraded in a ubiquitin/proteasome-dependent pathway 
(Demontis et al., 2006) 
 
 
1.4.4 The Role of Twist in Developing Tissues  
        Twist belongs to the bHLH class II protein family, which is actively involved in 
many developmental decisions such as osteogenesis, myogenesis, neurogenesis, and sex 
determination, and it was first described in Drosophila as a gene that regulates a series 
cell fate decisions in the mesodermal lineage. The genes identified in Drosophila to be 
regulated by Twist are listed in Table 4.  
 
        In the early stage of embryonal development, Twist is expressed in the invaginating 
ventral furrow cells. Homozygous Twist “knock-out” embryos die in the first few hours 
of Drosopila development due to failure to form mesoderm (gastrulation failure) with 
abnormal head involution and in the egg, the anterior end of the embryo is “twisted” 
(Simpson, 1983; Thisse et al., 1987). The name “Twist” is derived from the observation  
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of the “twisted” appearance” seen in the lethal mutants. At later stages, Twist is involved 
in mesodermal differentiation and muscle formation. In vertebrates such as mouse and 
human, Twist functions more actively and is involved in the “second gastrulation”, the 
highly conserved vertebrate process of neural crest migration. In Twist-null mice, the 
Twist-null embryo dies at day 11.5 with a failure of the cranial neural folds to close 
(Chen and Behringer, 1995), indicating that the most ancient and conserved function of 
Twist is to facilitate cell movement (Germanguz et al., 2007).   
 
Table 4. Genes activated by Twist during Drosophila development  
Gene Function References  
heartless (htl) FGF receptor Mesodermal migration  (Shishido et al., 1993; 
Beiman et al., 1996; 
Shishido et al., 1997; 
Gisselbrecht et al., 1996) 
Mesodermal development  (Lee et al., 1997) NK-4 ( also called msh2 and 
Tinman (tin) ) Heart/muscle development  (Azpiazu and Frasch, 
1993; Bodmer, 1993) 
Mef2 Muscle differentiation (Lilly et al., 1995; Bour et 
al., 1995; Taylor et al., 
1995) 
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        In vertebrates, Twist is also involved in cell differentiation during osteogenesis 
(Murray et al., 1992), myogenesis (Hjiantoniou et al., 2008), neurogenesis (Verzi et al., 
2002), hematopoiesis and cardiogenesis (Vincentz et al., 2008) in addition to mediating 
dorsao-ventral polarity as in Drosophila. In mice, Twist mediates growth and 
differentiation of the limb bud through SHH and FGF signal transduction pathways 
(O'Rourke et al., 2002).   
 
        In humans, mutations of the Twist1 lead to Saethre-Chotzen syndrome (SCS), an 
inherited autosomal–dominant craniosynostosis disease characterized by premature 
fusion of the calvarial bones, facial dysmorphisms, and limb abnormalities such as 
brachdactyly, duplication of distal phalanges, and cutaneous syndactyly (Reardon and 
Winter, 1994). After the syndrome was first described by Saethre and Chotsen in 1931-
1932, it was later mapped to mutations in human chromosome 7p21 by linkage analysis 
in the affected families as well as sporadic cases in 1990s (Brueton et al., 1992;Rose et al., 
1994) and Twist1 was identified as the responsible gene for the syndrome in 1997 
(Howard et al., 1997).  
 
        In osteogenesis, the sutures of the skull bone are the primary sites of bone formation 
and differentiation during development. Overexpression of Twist can de-differentiate the 
osteoblasts and keeps them in a osteo-progenitor-like state and decreasing the expression 
of Twist can lead to cell differentiation, indicating its critical role during cell type  
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determination (Lee et al., 1999). In oseteocyte/osteoblast cultures from SCS patients, 
Twist haploinsufficentcy has been shown to promote apoptosis (Yousfi et al., 2002), 
linking Twist’s function with cell survival.  
 
        Many studies reported that Twist usually plays a role as negative regulator in many 
cell types such as muscle and neurons. For example, in the direct interaction between 
MyoD and the basic domain of Twist, MyoD-mediated transactivation is inhibited 
(Spicer et al., 1996).   Therefore, it is not surpring that Twist, a known myogenic 
differentiation inhibitor,  is over-expressed in 50% of the tumors from 
rhabdomyosarcoma patients, in which tumor cells are derived from muscle precursor that 
fail to differentiate (Maestro et al., 1999).    
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1.4.5 The Role of Twist in Tumor Development   
The cellular functions of Twist in cancer cells are listed in table 5.   
 
Table 5 Functions of Twist in cancer cells 
Functions  Cell lines used in the 
studies  
References  
Anti-apoptosis  MEF,  
Neuroblastoma cells, 
(Yousfi et al., 2002; Maestro et 
al., 1999; Chen and Behringer, 
1995; Valsesia-Wittmann et al., 
2004; Sosic et al., 2003)  
Drug resistance Breast cancer,  
prostate cancer  
(Li et al., 2009; Wang et al., 
2004) 
Angiogenesis  Hepatoma, 
Breast cancer  
(Niu et al., 2007; Mironchik et 
al., 2005). 
EMT Breast cancer  (Yang et al., 2004) 
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1.4.5.1 Twist Inhibits Apoptosis and Promotes Drug Resistance    
        As mentioned above (section 1.4.2), in studies of rhabdomyosarcoma, Twist may 
play some roles in promoting tumorigenesis such as halting terminal differentiation and 
apoptosis inhibition (Maestro et al., 1999).  Twist has been shown to have anti-apoptotic 
effects in multiple cell lines in vitro and animal models (Yousfi et al., 2002; Maestro et 
al., 1999; Chen and Behringer, 1995). The anti-apoptotic function can be mediated 
through targeting the Arf/p53 pathway induced by c-myc, which cooperates with N-myc 
to promote tumor proliferation in neuroblastoma (Valsesia-Wittmann et al., 2004), 
modulating TNFα expression (Yousfi et al., 2002), inhibiting mdm2, or through 
stimulation of the NF-κB pathway (Sosic et al., 2003). 
  
        In addition to its involvement in differentiation and anti-apoptosis, Twist activity is 
also reported to contibrute to multiple drug resistacce in breast cancer and taxane 
resistance in prostate cancer (Li et al., 2009; Wang et al., 2004).  
 
 
1.4.5.2 Twist Mediates Angiogenesis    
 
        Twist also has been reported to mediate angiogenesis, as overexpression of Twist in 
human hepatoma samples correlates with high tumor microvessel density and increased  
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intra-/extra-hepatic metastasis (Niu et al., 2007).  In breast cancer cell lines and one 
xenograft mouse model, Twist overexpression is associated with increased vascular 
endothelial growth factor (VEGF) synthesis, suggesting the potential role in mediating 
angiogenesis through upregulation VEGF (Mironchik et al., 2005).  
 
1.4.5.3 Twist Promotes EMT and Cell Motility     
 
In addition to the functions mentioned above, Twist is well known to inhibit E-cadherin-
mediated cell-cell adhesions and induce cell motility, in a process called the epithelial-
mesenchymal transition (EMT) (Yang et al., 2004).  
 
1.4.5.3.1 Definition and Classification of EMT  
 
        EMT is a biological process through which an epithelial cell undergoes multiple 
biochemical and morphological changes to gain a mesenchymal cell phenotype. In 
contrast to the epithelial phenotype which is characterized by tight cell-cell junctions and 
interactions with basement membrane through its basal surface, the mesenchymal 
phenotype consists of a fibroblast-type morphology, loosened cell-cell interactions, 
andenhanced migratory and invasive capacity. As a result, the cells are usual more 
resistant to apoptosis and chemotherapy.  
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        EMT and the reverse process, the mesenchymal-epithelial transition (MET) are 
processes used during embryonic development to allow certain epithelial cells the 
capacity to transition back and forth between epithelial and mesenchymal status (Lee et 
al., 2006). Recently, EMT is classified into three subtypes (Kalluri and Weinberg, 2009):   
(1) Type 1 EMT: EMT during implantation, embryogenesis, and organ development  
(2) Type 2 EMT: EMT associated with tissue regeneration and organ fibrosis  
(3) Type 3 EMT: EMT associated with cancer progression and metastasis  
        The 3 subtypes of EMT are basically divided by the biological process, as there are 
no distinct differences between the involved signaling pathways. Type 1 is associated 
with  development, Type 2 is involved in tissue regeneration, and wound healing both of 
which have strong associations with inflammation, trauma, and/or tissue injury. Once 
inflammatory signals attenuate,, type 2 EMT tends to cease.  Yet when type 2 EMT 
perists in the absence of inflammatory signals, it leads to disease state-organ fibrosis, 
which is commonly seen in kidney (renal tubular fibrosis), heart (cardiac fibrosis), liver 
(liver fibrosis), colon (some spots in patients with Crohn disease)  and lung (idiopathic 
pulmonary fibrosis, Posttransplant bronchiolitis obliterans syndrome) (Zeisberg et al., 
2007a; Zeisberg et al., 2007b; Kim et al., 2006; Pollack et al., 2007; Bataille et al., 2008; 
Hodge et al., 2009). Type 3 EMT is used by cancer cells to invade and metastasize during 
cancer progression.  
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        Of note, cells involved in Type 2 EMT and type 3 EMT may be heterogeneous:  
some cells still continue expressing epithelial markers together with the acquired 
mesenchymal ones (also called “partial EMT”) , while others become fully mesenchymal 
phenotypes with complete loss of the epithelial markers (Kalluri and Weinberg, 2009).   
   
 
1.4.5.3.2 Pro-EMT Cytokines  
        Many signal pathways are activated by cytokines to initiate EMT. During 
gastrulation, Wnt/ fibroblast growth factor (FGF) and transforming growth factor-β 
(TGF-β) pathways as well as transcription factors snail, Eomes and Mesps have been 
reported to be actively involved in promoting the EMT (Skromne and Stern, 2001; Liu et 
al., 1999; Chea et al., 2005; Skromne and Stern, 2002).  During the EMT in neural crest 
formation, more signaling pathways such as BMP, c-Myb and msh homeobox 1 (Msx-1) 
are involved in addition to Wnt/FGF (Liem, Jr. et al., 2000; Karafiat et al., 2007).  
 
        In Type 2 EMT, participating growth factors or cytokines that have been reported 
include TGF-β1, EGF, FGF-2 and PDGF(Kalluri and Neilson, 2003; Strutz et al., 2002) 
 
        In type 3 EMT, many studies have shown the EMT-inducing signals such as TGF-
β1, tumor necrotic factor α (TNF-α), interleukin -6 (IL-6), EGF, and PDGF derived 
tumor cells and/or the tumor–associated stroma can activate downstream transcription  
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factor molecules including Twist, Snail, Slug, zinc finger E-box binding hoeobox 1 
(ZEB1), Goosecoid and FOXC2 (Thiery, 2002; Shi and Massague, 2003; Sullivan et al., 
2009; Colomiere et al., 2009; Grund et al., 2008; Hardy et al., 2010; Ding et al., 2010; 
Logullo et al., 2010). The cytokine/growth factors identified  in type 3 EMT are 
summarized in Table 6.  
Table 6 Cytokines/growth factors involved in type 3 EMT   
Cytokine/ 
Growth factors 
Cell lines  References  
HGF Hepatoma ,  
ovarian cancer  
(Ding et al., 2010; Vergara et 
al., 2010; Gotzmann et al., 2006)
EGF Breast cancer, ovarian cancer (Colomiere et al., 2009; Hardy 
et al., 2010; Vergara et al., 
2010) 
IL-6 Breast cancer (Sullivan et al., 2009; Colomiere 
et al., 2009) 
PDGF Malignant hepatocyte  
Prostate cancer  
Breast cancer  
(van et al., 2009; Kong et al., 
2009; Kong et al., 2008; 
Jechlinger et al., 2006) 
TGF-β Breast cancer ,  
Ovarian cancer 
Hepatoma   
(Shi and Massague, 2003; 
Logullo et al., 2010; Vergara et 
al., 2010; Gotzmann et al., 2006)
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1.4.5.3.3. Twist and EMT   
        EMT in cancer cells may not only play a role in mediating a cell’s migratory 
capacity and generating a high-grade, aggressive invasive cancer phenotype but also 
provide cancer cells with “stem cell like”properties . Twist was first to be reported in 
cancer-related EMT in a mouse breast cancer cell model (Yang et al., 2004).   It was 
subsequently found to be overexpressed in a variety of cancer and associated EMT 
phenotypes. Further support for Twist in tumor progression came from studies employing 
an siRNA approach to inhibit Twist expression which, in turn decreases the metastatic 
potential of tumor cells in animal models (Yang et al., 2004). 
 
1.4.5.4 Twist Overexpression in Human Cancers      
        To date, numerous clinical immunochemical studies have shown that Twist is 
overexpressed in multiple cancer cell types as listed in Table 7. The levels of Twist 
expression in cancers correlates with metastatic potential and invasiveness (Hoek et al., 
2004; Kwok et al., 2005; Rosivatz et al., 2002; Li et al., 2009; Maestro et al., 1999; 
Matsuo et al., 2009; Mikheeva et al., 2010).   
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Table 7  List of human cancers that overexpress Twist  
Cancers References 
Gastric cancer (Rosivatz et al., 2002) 
Rhabdomyosarcoma  (Maestro et al., 1999) 
Breast cancer  (Yang et al., 2004; Li et al., 2009) 
Neuroblastoma (Mikheeva et al., 2010) 
Hepatoma  (Matsuo et al., 2009) 
Melanoma (Hoek et al., 2004) 
Prostate cancer  (Kwok et al., 2005) 
Ovarian cancer  (Hosono et al., 2007) 
Nasopharyngeal cancer  (Song et al., 2006) 
Head and neck cancer  (Yang and Wu, 2008) 
Esophageal cancer (Sasaki et al., 2009) 
Myelodysplastic syndrome  (Li et al., 2010) 
Non-small cell lung cancer (Hung et al., 2009) 
Colon cancer (Valdes-Mora et al., 2009) 
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1.4.5.5 Downstream Targets of Twist in Cancer Cells  
        Although Twist is known to be a transcription factor, relatively few Twist regulated 
genes have been identified. As listed in Table 8, Twist can trans-activate AKT2, YB-1 
and Gli1, which are important for tumor metastasis and growth in cancers.  
 
Table 8 Transcriptional target genes of Twist from literature search  
Gene’s name  Action Functions  References  
AKT2 Activation migration (Cheng et al., 2008a) 
YB-1 Activation Resistance to DNA 
damage 
Tumor growth  
(Shiota et al., 2008) 
Gli1 Activation Tumor growth  
(rhabdomyosarcoma)  
(Villavicencio et al., 
2002) 
E-cadherin Repression Cell-Cell adhesion  (Yang et al., 2004) 
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1.4.6 Conclusion    
        Currently, Twist is regarded as an oncogene (Maestro et al., 1999; Valsesia-
Wittmann et al., 2004) since its over expression promotes colony formation of mouse 
embryonic fibroblasts in soft agar assay and participates in many important cellular 
function such as differentiation, anti-apoptosis and EMT, all of  which are important for 
tumor establishment and progression. Many recent studies have shown that Twist can 
modulate cancer stem cells, and lead to drug resistance (Vesuna et al., 2009). Efforts to 
knock down Twist expression in cancer cell lines and animal models have shown 
promising therapeutic effects on inhibiting tumor growth and metastasis (Kwok et al., 
2005). However, in spite of the importance and clinical associations of Twist expression 
in human tumors, the regulatory mechanisms of Twist expression as well as Twist’s 
downstream targets remain poorly understood. Understanding the mechanism for Twist 
regulation could lead to the identification of novel prognostic factors and therapeutic 
strategies for cancer patients. 
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II. Statement of Objective  
 
        Oral cancers are frequently preceded with oral submucous fibrosis (OSF) or other 
inflammatory conditions associated with periodontal disease or poor dental hygiene 
months to years before cancer development. OSF is a chronic, progressive, precancerous 
lesion of the oral mucosa (Ranganathan et al., 2006) and can elicit an inflammatory 
reaction. The pathologic examination of such lesions usually reveals extensive fibrosis of 
the epithelium, suggesting a result from EMT similar to those in other organs (Iwano et 
al., 2002). The pro-inflammatory cytokine, IL-6,  and Twist  are not only important for 
the development of precancerous lesions, but their expression has also been shown to be 
correlated with the clinical outcomes clinical studies of head and neck cancer patients 
(Allen et al., 2007a; Yang and Wu, 2008). In our preliminary studies using cDNA 
microarray analysis to profile metastatic SCCHN cells and compare them to isogenic but 
non-metastatic cells, we identified a relative increase in expression of Twist1, in the more 
metastatic cell line, suggesting that Twist may be an important player in mediating 
motility and metastasis in SCCHN cells (Su, Pickering and Myers unpublished 
observations). Furthermore, several studies have shown that IL-6 treatement can increase 
Twist expression and Twist-dependent EMT in cancer cells. Although both IL-6 and 
Twist correlate with the tumorigenesis as well as tumor progression of SCCHN and both 
serve as important markers for predicting patients’ prognosis, their relationship and the  
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mechanisms by which IL-6 can regulate Twist expression have not been clearly 
elucidated.   
 
        While Twist can be regulated by IL-6 at the transcriptional level through STAT3, 
HIF-1, and NF-κB, we have found that Twist expression can also be regulated at the post-
transcriptional level in SCCHN cells. While the sequence and secondary structure 
analysis of Twist predicts that its mRNA is quite stable, the Twist protein has a relatively 
short half-life between 1-2 hours. A comparative analysis of Twist in embryonic and 
adult tissues has shown a discrepancy between Twist mRNA expression and Twist 
protein expression, suggesting that Twist expression is regulated at the post-
transcriptional level (Gitelman, 1997; O'Rourke and Tam, 2002).   Therefore, we 
hypothesize that Twist expression is up-regulated by IL-6 stimulation of SCCHN cells at 
the post-transcriptional level and that this promotes SCCHN tumor progression.  As 
studies have shown that decreasing Twist expression in cancer cells can reverse the 
metastatic phenotype both in vitro and in vivo(Yang et al., 2004; Yang and Wu, 2008), it 
follows that a greater understanding the mechanisms of TWIST regulation could hold 
therapeutic implications for SCCHN patients. 
 
 Our working model is shown in Figure 2.1.  
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Figure 2.1 Working model for this project  
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The objectives of the project are:  
Part 1: to characterize the relationship between IL-6 treatment and Twist protein 
expression in SCCHN cells. The levels of secreted IL-6, receptor for IL-6, Twist mRNA, 
and Twist protein in response to IL-6 are assayed, analyzed, and characterized and the 
functional importance of this axis is defined in vitro.  
 
Part 2:  to determine the mechanisms by which  IL-6 stablizes Twist, preventing its 
degradation. Since the expression level of Twist responses to IL-6 within minutes, 
phosphorylation modulation rather than transcription regulation is hypothesized as the 
mechanism. In this part, a search of kinase candidates that regulate Twist stability in this 
signaling pathway is conducted and verified by experimental approach.  
  
Part 3: to identify the functional significance of the post-tranlational modification of 
Twist. Following part1, the most relevant functional consequence of Twist 
overexpression in SCCHN is increasing cell motiliy. In this part, phosphorylation site- 
modified Twist mutants are used to test the functional modulation by phosphor-
modulation. Both in vitro migration as well as the lymph node metastastic rate in an 
orthotopic oral cancer mouse model are examined and discussed.     
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III. Materials and Methods    
3.1 Drugs, Chemicals, Antibodies and Reagents  
        Cycloheximide (CHX), MG132, 2-Dimethylamino-4,5,6,7-tetrabromo-1H-
benzimidazole (DMAT ) or 4,5,6,7-tetrabromobenzotriazole (TBB ), U0126, AG490, 
SB202130 and SP600125 were purchased from EMD Chemicals (Gibbstown, NJ). 
Human recombinant IL-6 and CK2 kinase were purchased from Cell Signaling (Danvers, 
MA). Phospho-threonin (42H4) mouse mAb, CK-2α antibody, and Twist antibody were 
purchased from Cell Signaling Technology. Phosphoserine antibody was from Abcam 
(Cambridge, MA). Anti-HA antibody was from Roche Applied Science (Indianapolis, 
IN). Lipofectamine 2000 was purchased from Invitrogen. Nucleofector System was 
purchased from Lonza (Basel, Switzerland). CK2 kinase was purchased from Cell 
signaling. ATP, [γ-32P] was ordered PerkinElmer (Waltham, MA)   
 
3.2. Cell Culture 
        The cell lines were used for experiments included, 293T, a human embryonic 
kidney cell line; A549, a human lung cancer cell line, a panel of SCCHN cell lines from 
the primary tumor of patients with squamous cell carcinoma of the head and neck (FaDu, 
HN30, and MDA686-TU) and SCCHN cell lines from the metastatic lymph nodes of 
patients with SCCHN (OSC-19, HN31, and MDA686-LN). All cells were authenticated 
by STR analysis and found to be unique, except for HN30 and HN31 which were 
confirmed to be isogenic as they were derived from the same patient.     
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        All SCCHN cells and human 293T cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS), penicillin/streptomycin, L-glutamine, sodium pyruvate, nonessential amino acids, 
and a 2-fold vitamin solution. The A549 cell line is from human lung cancer and was 
cultured in RPMI 1640 supplemented with 10% FBS. All cells were grown in a 
humidified incubator at 37°C and 5% carbon dioxide. The cultures were free of 
Mycoplasma species and maintained for no longer than 8 weeks after recovery from 
frozen stocks. Neomycin-resistant stable cell lines were maintained in G418 (500 μg/ml).  
 
3.3. Western Blot 
3.3.1 Sample preparation  
        Cultured cells were washed with ice-cold PBS twice and then lysed with ice-cold 
RIPA lysis buffer (NP-40, 1%; deoxycholate, 0.5%; SDS, 0.1% , in PBS) supplemeted 
with fresh  2 mM NaF, 0.5 mM Na3VO4, 1X protease cocktail and kept on ice or 4ºC for 
30 minutes. Then cell lysates were collected by a cell scraper and placed in eppendorf 
tubes for centrifugation. After removal of the insoluble fraction the protein concentration 
of the samples was determined by DC Protein Assay kit (Bio-Rad, Hercules, CA).         
 
3.3.2 Immunoblotting  
        Each protein sample was diluted with 6X SDS sample buffer with freshly added β- 
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Mercaptoethanol, boiled at 95-100 ºC  for 10 min, and chilled on ice for 2-5 minutes. The 
samples were applied to each well of SDS-polyacrylamide gels (SDS-PAGE), 
electrophoresed, and electro-transferred to a PVDF (Polyvinylidene Fluoride) 
membranes. Then the membranes were blocked with either 5% non-fat dry milk, or 1% 
BSA, 10 mM Tris pH 7.5, 100 mM NaCl, 0.1% Tween 20) at room temperature for 30 
min or 45 min respectively. Then the membranes were first incubated with the primary 
antibodies (1:1000 dilution in 1% BSA-TBS-T ) at 4ºC over night, washed ,then 
incubated with secondary antibodies (fluorescence– or HRP (horseraddish peroxidase) - 
conjugated ) at room temperature for 0.5-2 hours. The bands were detected by Li-Cor 
imaging system or film development after ECL reagents added and quantified by 
software Image J.   
 
3.4. Immunoprecipitation  
        Immunoprecipitation was conducted on cell lysates prepared as above and with 
concentrations of approximately 1000 μg/ml of protein samples with 0.5μg IgG control or 
1-2 μg of antibody of interest according to the manufacturers’ recommendations. After 
gentle rotation at 4ºC overnight, 50 μl of pre-blocked agarose protein A or G beads were 
added for additional 1 h at 4 °C. Then the immunocomplex was washed for 4 times with 
complete IP lysis buffer 500 μl, vortexed, boiled at 95-100ºC for 5 minutes, and applied 
to a SDS-PAGE gel for electrophoresis and western blotting.          
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3.5. Immunocomplex Kinase Assay  
 
3.5.1 Generation of Hypo- & Hyper-phosphomimmetic Twist mutants 
        To facilitate immunoprecipitation and protein purification, we first cloned 6 myc 
tags and  6 his (hexa-his) into pcDNA3.1+ between BamH1 and EcoR1 using a standard 
PCR cloning procedure with sequence verification. The entire human Twist cDNA 
coding sequence (NM_000474) was then cloned into EcoR1 site.  
        Point mutations were introduced by PCR using the QuikChange® Multi Site-
Directed Mutagenesis Kit following the manufacturer’s protocol (Stratagene, Cedar 
Creek, TX). The primer information for each condition is listed in Table 9.  All of the 
inserted sequence was confirmed by using ABI PRISM 3730 DNA analyzer (Applied 
Biosystems, Foster, CA, USA) at the DNA core facility at UT MD Anderson Cancer 
Center.  
 
 
Table 9  Primer sequences for Twist mutants using  in situ mutageneis  
S18,20A-Twist  - tcgccggccgacgacagcctggcaaacgcagaggaagagccagaccggcagc- 
S18,20D-Twist  - tcgccggccgacgacagcctggacaacgacgaggaagagccagaccggcagc- 
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3.5.2 Kinase Assay 
        The immunocomplex kinase assay was carried out in human 293T cells 48 hours 
after transfection. The Myc-Tagged Wild-type (WT) Twist and S18,20A –Myc- Twist 
were immunoprecipitated with Myc antibody then incubated with recombinant CK2 
kinase (Cell Signaling) and 1μCi γ-P32-ATP in kinase buffer for 15 min at 30 °C. Then 
the reactions were terminated by adding 6X SDS sample buffer and boiling at 95-100 °C 
for 5 minutes. All the samples then were electrophoresed in SDS-PAGE, electro-
transferred to PVDF membranes and subsequent autoradiography or western blotting.    
 
3.6. Transfection 
3.6.1 Lipofectamine Transfection  
        For 293T cell transfection, 4-6 x 106 cells were plated onto 10cm dishes in order to 
reach 90-100 % confluency 24 hours before transfection.  Lipofectamine 2000 20μl was 
diluted in 250 μl PBS at room temperature for 5 min (Mix 1).  Plasmids (5 μg) were 
then diluted in  250 μl PBS and mixed well with Mix1 and left at room temperature for 
20 min.  Before transfection, the cells were incubated in 5 ml of serum free medium. 
Then the plasmid / lipofectamine mixture was added drop by drop directly into the 
culture dish and the cells were kept at 37°C in the incubator for 4-6 hours. After 
replacing the serum free media with 10% serum containing media, the cells were left to 
grow for 48 hours before harvest for western blot or immunoprecipation.    
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3.6.2 Electroporation  
        For difficult–to-transfect SCCHN cells, electroporation was used. The experiment 
was carried out in Nucleaofector System (Lonza, Basel, Switzerland) with solution V. 
For this method, 2x106 cells were suspended well in 100 μl of electroporetion buffer and 
mixed with plasmid DNA (4 μg).  Then electroporation was carried out on the mixture in 
an electroporation cuvette using different programs according to cell lines. (V-020 for 
OSC-19, T-001 for HN30/HN31, and X-001 for A549, use). The electroporated cells 
were then recovered in pre-warmed (37ºC) serum-free RPMI 500 μl for 5 min and 
transferred to 6-well plates and placed in the incubator.  
 
3.6.3 Selection of Stable Clones 
        For establishment of stable lines (HN31-control, HN31-WT_Myc-Twist, HN31-
S18,20A-Myc-Twist, and HN31-S18,20D-Myc-Twist) , G418 (Neomycin) 500 μg/ml 
was added to the complete medium 48 hours after transfection together with a control 
plate without transfection. Starting at the 4th week after selection, all (100%) of the cells 
in the control plate died while a portion of the transfected cells still grew. These cells 
were then expanded and cryo-preserved for future experiments.      
 
3.7 CK2 Kinase Activity Assay  
        Cell lysates were collected in hypo-osmotic buffer after treatment with PBS 
(control) or IL-6 (20ng/ml) for 30 min, and the cell lysates (5 μg), synthetic peptide CK2    
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substrate (RRRADDSDDDDD; 0.1 mM )(Genescript, Piscataway, NJ), and  γ-P32-ATP 
were incubated in the assay dilution buffer for 10 min at 30 °C. The phosphorylated 
substrate was then separated on P81 phospho-cellulose paper and quantified with a 
scintillation counter.  
 
3.8. Real Time RT-PCR  
        The RNA was extracted from cells with RNeasy ® Mini Kit (Qiagen, Valencia, 
CA), and real time RT-PCR was carried out with Verso 2-step QRT-PCR kit (Thermo 
Fischer Scientific, Worcester, MA) that uses SYBR fluorescent dye to detect the 
amplified PCR product.  The relative gene expression was normalized to endogenous 
GAPDH expression. The primer information was listed in the below table:  
 
Table 10 Primer information for real time PCR  
Gene Primer’s name Product size Primer sequence  
Forward Cctctaccaggtcctccaga Twist  
Reverse  
150 bp 
Cagaatgcagaggtgtgagg 
Forward Tgagctcagatatcgggctga IL-6R 
Reverse  
86 bp  
Cgtcgtggatgacacaagtgat 
Forward Atcatccctgcctctactgg GAPDH 
Reverse  
188 bp 
Ccctccgacgcctgcttcac 
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3.9 IL-6 Enzyme-Linked Immunosorbant Assay (ELISA) 
        The secreted IL-6 in the supernatants of cultured cells was determined with a 
Human IL6 immunoassay (ELISA) kit (R&D systems, Minneapolis, MN). Briefly, the 
cells were cultured to subconfluency and serum starved overnight before replacement 
with 2% serum containing medium for 48 hours. The supernatants were then centrifuged 
at 2000 rpm for 6 minutes to remove the floating cells before assaying for IL-6 
expression. Meanwhile, the cultured cells were trypsinized and the total numbers of cells 
were counted. The data was expressed as pg/million cells.    
 
3.10 Transwell Mirgration Assay  
        The transwell migration assay was performed in 24-well BioCat control inserts (BD 
Biosciences, San Jose, CA) with an 8μm pore size polycarbonate filter. The lower 
chamber contained 700 μl of 10% medium as a general chemo-attractants . Cells were 
washed once in serum free medium and plated onto the upper chamber in 500 μl of serum 
free medium to create a concentration gradient toward the lower chamber. The 
experiment was carried out within 20-22 h after cell plating and incubation in a 37 ºC 
incubator. The non-migratory cells on the membranes were removed by cotton rod 
swiping and the migrated cells were stained for cell counting.  
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3.11 Orthotopic Xenograft Tongue Cancer Mouse Model  
        The care, use, and treatment of all of the animals in this study were in conducted on 
an Institutional Animal Care and Use Committee (IACUC) approved protocol. For the 
orthotopic xenograft nude mouse model of tongue cancer, 5x104 cells from each stable 
cell line established from the HN31 cell line were suspended in 30 µL of serum-free 
Dulbecco modified Eagle medium (DMEM) and injected into tongues of athymic nude 
mice. The mice were examined twice a week for weight loss and tumor measurement 
with calipers. If a mouse lost more than 20% of their preinjection body weight, 
euthanasia was performed. Fourteen days after tumor injection, all mice were sacrificed 
and necropsy was performed with removal of tongue tumors and  cervical lymph nodes. 
All tumors and cervical lymph nodes were fixed in formalin and embedded in paraffin for 
hematoxylin-eosin (H&E) and pan-cytokeratin (Lu-5) staining for evaluation of 
metastasis. 
 
 
3.12 Statistical Analysis 
        Statistic analyses were carried out in the SPSS 16.0. For comparing the means from 
two independent groups, two-sided Student’s t test was used in all statistical analyses.  
H0 : is null hypothesis , supposing the means from the two groups are equal ; 
H1: is alternative hypothesis , supposing the means from the two groups are not equal.  
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Statistical significance was accepted when the P value was less than 0.05, which means if 
the means are equal as null hypothesis, the chance to have the result is less than 5 in 100. 
The smaller the P value, the higher the chance to reject H0. Since the H0 is rejected, we 
conclude there is significant evidence to support H1.   
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IV. Results  
4.1. IL-6 production and biological functions in Squamous Cell Carcinoma of Head 
and Neck Cells in vitro  
 
4.1.1. The Expression of the Receptor for IL-6 (IL-6R) and IL-6 in SCCHN Cells  
        It has been reported that most non-small cell lung cancer and squamous cell 
carcinoma of head and neck (SCCHN) cell lines express the receptor for IL-6 (Shinriki et 
al., 2009). To further characterize the level of the receptor for IL-6 (IL-6R) in SCCHN 
lines, mRNA for IL-6R was quantified by real-time RT-PCR. As shown in Figure 4.1, 
there is no expression of IL-6R in the human immortalized keratinocyte epithelial cell 
lines HOK16B and NOM (normal oral mucosa) 9.  In contrast, all of the SCCHN cell 
lines examined had elevated IL-6R relative to HOK16B or NOM 9 control lines (all 
p<0.05 by student t’s test) .   
 
        The secreted IL-6 in the supernatants of cultured SCCHN cells was determined 
using a human IL-6 ELISA kit as described in section 3.9. As shown in Table 11, all of 
the SCCHN lines excreted increased levels of IL-6 relative to conditioned culture media 
from immortalized human keratinocye cell lines.  
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Figure 4.1 Relative expression of the receptor for IL-6 (IL-6R) in SCCHN cells  
        The levels of IL-6R mRNA expression were normalized to the expression levels of 
the housekeeping gene GAPDH and were expressed as the mean fold change from basal 
± s.e.m. Because there is no detectable mRNA expression in HOK16B and Nom 9 lines, 
all expression levels were normalized to SQCCY1.   All experiments were done in 
triplicate for each cell line. (*: p<0.05)    
 
Table 11  Levels of secreted IL-6 in SCCHN cell lines 
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4.1.2 Proliferation Rate of SCCHN Cells in Response to Exogenous IL-6 Treatment  
        Since all the SCCHN lines express various levels of IL-6R and IL-6, next we 
determined the effect of exogenous IL-6 on proliferation of these cells. Cell proliferation 
was measured by MTT assay after 48 hours treatment of the cells in IL-6-containing 5% 
DMEM. As shown in Figure 4.2, there is a dose-dependent inhibition of cell proliferation 
with IL-6 treatment.  
 
 
 
Figure 4.2 Proliferation rate of OSC-19 SCCHN cells in the presence of IL-6  
        A total of 100,000 cells were plated into each well in 1ml volume in a 24-well plate. After 
the cells had attached they were serum starved overnight, and the medium was replaced with 5% 
DMEM containing IL-6 at the indicated concentration for 48 hours. On the day of harvest, 200 μl 
of MTT solution (2 μg/ml) was added to each 1-ml medium for 2 hours. Then the cells were lysed 
and prepared for optic density (OD) measurement by adding 1ml of DMSO each well after all the 
remaining medium was aspirated. The y-axis in the figure shows the OD at 570 μm wave length 
in a plate reader. (*: compared with no treatment group (concentration =0), p<0.05 by student t’s 
test)  
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4.1.3 IL-6 as a Chemoattractant in Transwell Migration Assay  
        To determine if IL-6 is a chemoattractant for SCCHN cells, the transwell migration 
assay was performed with various concentration of IL-6 added to the 0.1% serum 
containing DMEM in the lower chamber while 200,000 cells of OSC-19 were plated onto 
the upper chamber in 0.5 ml of serum free medium.  The migratory cells were determined 
after 22 h of incubation.  
 
 
A.                                                                   B. 
 
 
Figure 4.3 IL- 6 as a chemoattractant in trans-well migration assay  
A.  The average number of migratory SCCHN cells in each condition is expressed as 
average number of cells/200 per high powered field ± s.e.m. *: represents P<0.05 by 
student t’s test comparing treated and control (IL6 =0) groups. B. Representative pictures 
for each condition are shown in the lower panel. The motility of SCCHN cells is 
increased as the concentration of IL-6 is increased. 
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4.1.4 IL-6 Promotes the Motility of SCCHN cells  
        In order to further assess the impact of IL-6 treatment on cell motility, OSC-19 
SCCHN cells were pre-treated with IL-6 at 20ng/ml for 24 h then re-plated onto the inner 
chamber for studying the cell migration in a trans-well assay. As shown in Figure 4.4, the 
IL-6 pre-treated SCCHN cells have greater motility relative to the control group with 
P<0.05. The lower panel showed the representative pictures under microscopic exams in 
the corresponding conditions.   
 
 
   
 
Figure 4.4 IL-6 pretreatment of OSC-19 SCCHN cells increases the cell motility in a 
trans-well migration assay. *: P<0.05 by student t’s test  
 
No IL-6 pretreatment IL-6 pretreatment x 1d 
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4.1.5 Changes of EMT Markers under IL-6 Stimulation in SCCHN  
        Because EMT is frequently associated with increased cell motility as reviewed in 
Section 1.4, we next examined the impact of IL-6 treatment on the expression of EMT 
markers in OSC-19 SCCHN.  The cells were serum starved overnight then treated with 
IL-6 20ng/ml and harvested for western blotting at the indicated times. As shown in 
Figure 4.5, the protein expression levels of Twist increased over time while the epithelial 
marker E-cadherin and Snail, a mesenchymal marker, remained at similar levels.  α-SMA 
(smooth muscle actin), another mesenchymal marker for EMT, appeared briefly after 3-6 
h of IL-6 treatment and went back to the basal level. These data show differential effects 
on the expression of EMT markers on IL-6 stimulation. 
 
 
Figure 4.5 Changes of EMT markers following IL-6 treatment in SCCHN cells.                                        
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4.1.6 Conclusions and Discussion 
 
        In our preliminary data, almost all SCCHN cells express receptors for IL-6 and 
secrete varying levels of IL-6 into the culture medium. Despite the presence of an 
apparent autocrine loop, some of the cells still can response to exogenous IL-6 
stimulation, suggesting that the receptors for IL-6 were not saturated. The hypothetical 
model of how IL-6 works on SCCHN tumor cells through autocrine/paracrine and 
systemic pathways is illustrated in Figure 4.6. We found that IL-6 promotes cell motility 
as well as induction of several mesenchymal markers of EMT.  Although morphological 
EMT was not observed following short-term stimulation of IL-6 (data not shown), the 
appearance of mesenchymal markers in the epithelial cancer cell lines suggest at least 
partial EMT induction by IL-6. Of all the mesenchymal markers tested, the levels of 
Twist expression continue to increase with the length of exposure to IL-6, suggesting that 
Twist is a downstream target of the IL-6 signaling pathway.  This observation is 
examined further in the following sections.   
 
        Several research and clinical studies have shown that IL-6 promotes cancer cell 
proliferation and tumorigenesis (Mueller et al., 2010; Lederle et al., 2010; Pitulis et al., 
2009; Grivennikov et al., 2009), however, there are discrepancies between in vivo and in 
vitro studies(Regis et al., 2009; Knupfer and Preiss, 2007). Consistent with the published 
results of other investigators, we observed an IL-6 dose-dependent inhibition of SCCHN  
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cell growth in vitro cultures (Figure 4.2). Whether or not this is cell- line specific or 
whether it is only specific for in vitro condition needs to be evaluated in further 
experiments. As reviewed in section 1.3.2, the status of chromosome 9p21 (INK4/ARF)  
may also contribute to the inhibitory effects of IL-6. Since 9p21 deletion is commonly 
seen in oral premalignant lesions as well as SCCHN in 39-67% of these patients (Gollin, 
2001), it will be worthwhile to incorporate genetic information regarding this locus along 
with a cell’s growth response to IL-6 in future experiments.       
 
 
4.2. Twist Regulation by IL-6 in SCCHN Cells 
 
4.2.1 Time–Course of Twist Regulation by IL-6   
 
        Since we have shown that the up-regulation of Twist by IL-6 is the most striking 
changes among the EMT markers, we next examined the impact of IL-6 treatment on 
Twist expression in a shorter period (0-4h). All cell lines used in Figure 4.6 are from 
SCCHN except A549 and H1703, which are lung cancer cells. As shown in Figure 4.7, 
Twist expression is up-regulated shortly after IL-6 treatment in not only OSC-19- but 
also in HN31-, FaDu-, & MDA 686-LN- SCCHN. Of note, Twist up-regulation after IL-6 
treatment is also observed in the lung cancer cell line A549, indicating that the  
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phenomenon is not cell-type specific or tissue-specific. In this figure, there are three 
“paired”or “isogenic” cell lines, e.g. HN30 & HN31, MDA686-TU & MDA686-LN, 
UMSCC17A & UMSCC17B, which were established from primary tumors (HN30, 
MDA686-TU, UMSCC17A) or metastatic lymph nodes (HN31, MDA 686-LN, 
UMSCC17B) of the same patients. Two out of these paired cell lines showed the Twist 
up-regulation is increased in the metastatic lines as compared to the lines of the primary 
sites, suggesting an underlying different biological response to IL-6 in metastatic lines. 
This is also observed in other lines established from metastatic LNs such as OSC-19.  
 
Figure 4.6 Hypothetical model for how IL-6 works on SCCHN tumors 
IL-6IL-6
SCCHN cancer cells 
Blood vessel
Autoc rine/ 
paracrine
st imulation Systemic 
stimulation
Stroma cells 
IL-6R 
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Figure 4.7 Twist expression in response to IL-6 stimulation in SCCHN cells  
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4.2.2  Up-regulation of Twist by IL-6 is Transcription-independent 
        Since Twist has been reported to be a transcriptional target of STAT3 (Lo et al., 
2007), which is also a major downstream target of IL-6 signaling, we evaluated whether 
IL-6 regulates Twist expression at the transcriptional level.  Using RT-PCR for Twist, the 
level of Twist mRNA was examined in IL-6 treated HNSCC cells.  
 
 
 
 
 
 
 
 
Figure 4.8 Twist mRNA expression in response to IL-6 stimulation in OSC-19 
SCCHN cells 
 
        The experiments have been performed in duplicate in the OSC-19 and HN-31 
SCCHN liness. Figure 4.8 shows a representative result from OSC-19 with the 
corresponding expression levels of Twist mRNA quantified by real-time PCR. Values 
were normalized to the expression levels of the housekeeping gene GAPDH, and are 
expressed as the mean fold change from basal ±  s.e.m.  
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        In contrast to the dramatic increase of the Twist protein after IL-6 treatment, Twist 
mRNA levels remained relatively unchanged under the same experimental conditions, 
indicating an underlying transcription-independent mechanism controlling the increase in 
Twist expression that is induced by IL-6 treatment.  
 
4.2.3  IL-6 Upregulates Twist Expression by Inhibiting Its Degradation 
        The observation that IL-6 up-regulates Twist expression post-transcriptionally led us 
to investigate whether or not the degradation of Twist was in turn modulated after IL-6 
treatment.  
A.  
 
B. 
 
 
 
 
 
 
Figure 4.9 IL-6 upregulates Twist expression by inhibiting its degradation  
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         As shown in Figure 4.9 (A) the expression of Twist protein in OSC-19 SCCHN 
cells is induced rapidly after treatment with the proteasome inhibitor MG132, suggesting 
Twist is degraded through a proteasomal degradation pathway.   
 
        To determine the half-lif of Twist (Figure 4.9(B), cells were treated with CHX, a 
protein synthesis inhibitor and cell lysates were collected at 0, 15, 30 min and 1, 2, 4 h 
and the amount of protein at each time point was determined by western blotting and 
quantified by densitometry. In Figure 4.8, the steady state of Twist has a half-life of 1.2h. 
In the presence of proteasome inhibitor MG132 or IL-6, less Twist is degraded and the 
half-life is not achieved in this experiment, indicating that IL-6 up-regulates Twist 
expression through inhibiting its degradation.   
 
4.2.4 Conclusions and Discussion  
        Twist can be upregulated by IL-6 treatment of SCCHN cell lines through inhibition 
of Twist degradation.  Though, it has been reported that Twist is a transcriptionally up-
regulated by STAT3, a major downstream of IL-6 (Lo et al., 2007). Twist protein levels 
elevate at a faster rate than mRNA levels. Consistent with previous studies (Demontis et 
al., 2006), our data support that Twist is degraded through a ubiquitin/proeasome 
degradation pathway since levels of the short-lived Twist can be stabilized by the 
proteasome inhibitor MG132. Given the concept that the high GC content of Twist 
mRNA may contribute to its stability as discussed in Section 1.4.2, the expression of the  
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Twist protein may be largely controlled at the post-transcriptional level in this system. 
Thus, Twist is maintained at a low basal level with very short half-life; and when external 
factors such as EGF or IL-6 ar available, Twist is stabilized and up-regulated within a 
short time to meet the needs for cell survival , migration, or differentiation.   
 
4.3 Determination of the Potential Downstream Target to IL-6 to Stabilize Twist  
4.3.1 Twist is Phosphorylated in Response to IL-6  
 
        Post-transcriptional modification of transcription factors, especially through 
phosphorylation, has been shown to be important for regulating their function as this 
provides a mechanism for cells to rapidly initiate transcriptional programs in response to 
external stimuli (Holmberg et al., 2002). Therefore, we examined whether or not Twist 
can be phosphorylated in response to IL-6 treatment by immunoprecipitating the treated 
Twist protein from IL-6 treated cells and performed western blotting with antibodies to 
phospho-tyrosinemor phospho-serine/phospho-threonine. Limited by the poor efficiency 
of current commercially available antibodies to immunoprecipitate endogenous Twist, 
SCCHN cells transiently transfected with HA-tagged Twist were used for this HA pull-
down assay.  Although there was no band detected by the anti-phospho-tyrosine antibody 
(data not shown), there was a clear increase in phospho-serine detection following IL-6 
treatment. (Figure 4.10)   
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Figure 4.10 Twist is serine-phosphorylated by IL-6 treatment 
 
4.3.2 Signaling Pathway Inhibitor Screening Assay  
        To determine  the potential downstream signaling pathway responsible for Twist 
phosphorylation after IL-6 stimulation, we used an inhibitor screening strategy to test 
whether or not any known canonical signaling pathway is participating in the stabilization 
of the Twist protein throught its phosphorylation.  .  
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       As shown in Figure 4.11, Twist can be up-regulated by IL-6 in spite of the usage of 
inhibitors blocking JAK (AG490), PI-3 kinase (Wortmannin), Erk (U0126), p38 MAPK 
(SB202130), and JNK (SP600125) pathway, indicating the Twist up-regulation is 
independent of these pathways.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Inhibitor screening assay shows Twist up-regulation by IL-6 is 
independent of the known canonical signaling pathways.  
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4.3.3 CK2 Phosphorylation Motif on Twist is Conserved Across Species  
        Since none of the known pathways that we tested appeared to be involved in 
mediating the IL-6 - induced phoshporylation of Twist, we next scanned the amino acid 
sequence in the webserver http://hits.isb-sib.ch/cgi-bin/PFSCAN, and we identified a 
CK2 substrate consensus motif (SNSE) within Twist at residues 18 through 21 that is 
conserved across species (Figure 4.12).  
 
 
 
 
 
 
Figure 4.12 Predicted CK2 phosphorylation motif is conserved across species. 
 
 
4.3.4  CK2 Inhibitors Destabilize Twist in Response to IL-6  
To determine whether CK2 could be mediating the IL-6 induced stabilization of the 
Twist protein, we evaluated the effect of small molecule inhibitor of CK2, DMAT and 
TBB on Twist expression afterIL-6 treatment. As shown in Figure 4.13 both DMAT and 
TBB were able to block the up-regulation of Twist by IL-6 at very low concentrations in 
more than one cell line.   
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Figure 4.13 Twist expression is blocked by CK2 inhibitors  
 
4.3.5   CK2 shRNA Decreases Twist Levels in IL-6-treated SCCHN Cells 
        To confirm the findings seen with the CK2 inhibitors, we next examined  the effect 
of short hairpin (sh) RNAs specific for the catalytic subunit of CK2 (CK2α) on the IL-6 
induced elevation of Twist levels in SCCHN cells.  
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       To initiate these studies, OSC-19 SCCHN cells were electroporated with either 
control vectors or shRNA to CK2α for 24 hours. The cells were then treated with either 
IL-6 20 ng/ml or PBS control for 30 minutes and lysed for subequent western blotting for 
Twist protein. As shown in Figure 4.14, IL-6 failed to up-regulate Twist protein level 
when the CK2 expression was diminished with two different shRNA constructs.   
  
 
 
Figure 4.14  CK2α shRNAs block  Twist upregulation by IL-6  
 
4.3.6  CK2 Kinase is Activated by IL-6  
        CK2 is a ubiquitous serine/threonine kinase regulating many relevant biologic 
processes, including inflammation (Cozza et al., 2010) that used to be regarded as a 
constitutively active intracellular kinase. However, several recent studies showed CK2  
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can be activated in response to external stimuli although though underlying mechanisms 
remain unclear (Litchfield, 2003).  
        We next evaluated the effect of treating SCCHN cells with IL-6 and found that the 
CK2 kinase is activated by IL-6 as assessed by a specific CK2 kinase assay (Figure 4.15).  
 
 
Figure 4.15 CK2 kinase activity assay shows CK2 kinase activity is increased by IL-
6 in HN31-SCCHN cells.  
 
        To initiate this study, HN31 SCCHN cells were serum starved overnight, pretreated 
with DMSO or DMAT (10 μM) for 1h, and treated with either phosphate-buffered saline 
(PBS) (control) or IL-6 (20 ng/ml) for 30 minutes. The endogenous CK2 activity was 
then examined in the cell lysates (5 μg) by using a synthetic peptide CK2 substrate 
(RRRADDSDDDDD; 0.1mM) and γ32P-ATP and counting the radioactive uptake  
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 (Pagano et al., 2004). The y-axis represents the count per minute (CPM) of the 
radioactivity after normalizing to the control (no substrate).  
 
4.3.7 Conclusions and Discussion  
        In this section, we determined that CK2 is in the pathway between IL-6 and Twist 
up-regulation by using a CK2 inhibitors, shRNA, and a CK2 kinase activity assay.  
 
        Although CK2 has been shown to be activated by many factors and conditions 
including serum, DNA damage, growth factors and cytokines (as reviewed in section 
1.3.3), the mechanisms of CK2 activation are still not known. Using a web-based 
computational prediction of the phosphorylation motifs within the CK2α and CK2β 
amino acid sequences, only several Erk phospohrylation consensus motifs have been 
found. Although it has been reported experimentally that Erk2, not Erk5 is responsible 
for CK2α activation by EGF stimulation in neuroblastoma cells (Ji et al., 2009), in our 
SCCHN lines, as shown in Figure 4.11, phosphor-Erk is not increased by IL-6 and 
blocking Erk activation with U0126 did not blocks the effect of Twist upregulation by IL-
6.  These findings suggest an Erk-independent pathway is responsible for CK2 activation 
by IL-6. Since the computational prediction could not provide us more information of the 
unknown kinase responsible for CK2 activation, alternative approachs such as Mass 
Spectrometry to identify the potential phosphorylation site(s) on CK2, or phosphoprotein  
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array comparing untreated and treated samples may help us to identify the potential 
targets that mediate signaling between IL-6 and CK2. .  
 
4.4  Protein Interaction Between Twist and CK2 
4.4.1  In 293T Transient Transfectant Lysates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 CK2α interacts with Myc-Twist in 293T transient transfectant lysates 
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        In Section 4.3, we demonstrated that CK2 is in the pathway between IL-6 and Twist 
up-regulation and that the Twist transcription factor is phosphorylated by IL-6 treatment. 
The observation prompted us to investigate whether or not there is a direct interaction 
between CK2 and Twist.  
        To address the question, 293T cells were transfected with both wild-type Myc-Twist 
and the catalytic subunit of CK2 (CK2α) for 48 hours. The lysates then were subjected to 
immunoprecipation with either anti-CK2α antibody or anti-Myc antibody, followed by 
western blotting.  
        As shown in figure 4.16, CK2α was co-immunoprecipitaed with Myc antibody and 
vice versa. The bidirectional co-immunoprecipitation experiments suggest that CK2α and 
Myc-Twist are found within a protein complex.  
   
 4.4.2 Co-immunoprecipitation in FaDu Cell Lysates 
        Because of the concern that non-specific protein interaction can occur in co-
immunoprecipitation studies using transient protein over expression systems in which the 
proteins are over-expressed , we next examined if the protein interaction can be identified 
with the endogenous CK2 and Twist proteins in SCCHN cells.   
        The FaDu cell line was chosen for this study because it has a high basal levels of 
CK2 protein. In Figure 4.17, endogenous Twist (MW: 26 kDA) was co-precipitated with 
CK2α pull-down, indicating there is interaction between CK2 and Twist in SCCHN cells.  
 103
 Results 
 
Figure 4.17 Endogenous CK2α interacts with Twist in Fadu SCCHN cells 
 
    
 
 
 
 
 
 
 
4.4.3. Co-immunoprecipitation in Myc-Twist Stably Expressing HN31 Cell Lysates  
        In order to further study the interaction between Twist and CK2α by, we established 
a Myc-Twist stable expression HN31-SCCHN cell line by stable transfection through 
G418 selection, as all currently available Twist antibodies from Cell Signaling, Sigma-
Aldrich, and Santa-Cruz were found to have very poor efficiency in immunoprecipitating 
endogenous Twist. 
        In Figure 4.18, CK2α is co-immunoprecipitated in the HN31- anti-myc 
immunoprecipitants, further supporting the interaction between the two proteins in 
SCCHN cells.  
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Figure 4.18 Endogenous CK2α interacts with Myc-Twist in HN31 SCCHN cells  
 
4.4.4 Conclusions and Discussion 
        Immunoprecipitation is one of the commonly used approaches to demonstrate 
protein-protein interactions. Because the commercially available Twist antibodies do not 
work well for immunoprecipitation in our hands, a small epitope Myc tag was added in 
front of Twist as a fusion protein in an expression plasmid in for immunoprecipitation 
purposes. From the first experiment using 293T transfectiant lysates, the interaction 
between CK2α and Myc-Twist was demonstrated using bi-directional 
immunoprecipitation. The two proteins were found to interact endogenously within 
SCCHN cells and this was further demonstrated in the immunoprecipiation experiment in 
FaDu and HN31-Myc-Twist over expression stable lines. Thus, we provide evidence that 
there is interaction between the two proteins in different approaches and cell lines. One of 
the disadvantages of this type experiment is that the proteins co-immunoprecipiated may 
not necessarily interact directly but rather through a third docking protien. To further   
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answer the question, an in vitro GST protein pull-down assay using proteins isolated from 
a bacterial protein expression system should provide complementary information. 
4.5  Twist Phosphorylation by CK2   
4.5.1  Mapping the Phoshporylated Twist Residue by Immunocomplex Kinase Assay  
        As mentioned in Section 4.3.3, there is a putative CK2 phosphorylation site (SNSD) 
between the 18th and 21st amino acids of Twist as determined by sequence analysis for the 
CK2 phosphorylation motif. To determine whether or not CK2 directly phosphorylates 
Twist at this site, we performed immunocmoplex kinase asay in 293T cells over 
expressing either wild-type (WT) Myc-Twist or mutant Myc-Twist in which the S18 and 
S20 are substituted with alanine by site-directed mutagenesis (S18,20A). As shown in 
Figure 4.19A, the amino acid alanine (A) is structurally similar to serine (S) except the –
OH residue on the second carbon, therefore alanine can not be phosphorylated by a 
kinase and therefore functionally mimics the unphosphorylated serine. As shown in 
Figure 4.19 B, the purified CK2 kinase can phosphorylate WT Twist, but this 
phosphrylation is strongly reduced in Twist S18,20A. Furthermore, this phosphorylation 
is also abolished in the presence of the CK2 inhibitor, DMAT. The experiment was done 
using different tagged forms of Twist (HA-Twist in figure 4.18B and Myc-Twist in 
Figure 4.19C), with both experiments showing consistent results.  
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B.  
 
 
 
 
 
 
 
C.  
 
 
 
 
 
 
 
Figure 4.19 Immunocomplex CK2 kinase assay    
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4.5.2 Mass Spectrometry  
        To more definitively demonstrate the site where the phosphorylation of CK2  occurs 
in IL-6 treated SCCHN cells, mass spectrometry was attempted several times. To 
increase transfection efriciency, electroporation was opitimized and stable cell lines were 
established. However, even when using the Twist stable expression cell lysates, the 
protein detected by western blotting was not enough for subsequent mass spectrometry 
phospho-site identification. 
 
  
 
 
 
 
 
 
 
Figure 4.20 Coomassie gel staining for mass spectroscopy and corresponding 
western blotting   
        As shown in Figure 4.20, the corresponding protein band in Coomassie gel staining  
(left) is weak in contrast with the clear band by IP western blotting (right, arrow, IP: myc , 
IB: Myc)  
IgG IP:MycIP:Myc
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4.5.3 Conclusions and Discussion  
        In the section, we show the evidence that Twist is a substrate by CK2 as the γ-P32 – 
ATP incoporation is increased after CK2 kinase is added to the Twist/γ-P32-ATP/kinase 
buffer mixture. By either adding CK2 inhibitor or substitution of the potential 
phorphorylated serines with alanines, the phosphorylation is diminished, supporting our 
hypothesis. To demonstrate that the phorphorylation can occur in cancer cells, mass 
spectrometry was tried several times, however, was not successful due to insufficient 
Myc-Twist protein was immunoprecipitated by Myc antibody. To further improve the 
assay, we may repeat MS by using GST-Twist pull-down assay which can enrich the 
protein in the gel or try to raise mice that produce monoclonal antibody against the 
phospho-Twist protein and test the antibody in vitro and in vivo.   
 
        Of note, the identified CK2 phosphorylation site is with the NSEE motif (as 
reviewed in section 1.4.2). NSEE is a highly conserved sequence domain at N-terminus 
and the function is unknown to date (Singh and Gramolini, 2009). Our data may 
contribute to the current knowledge of the function of this motif.  
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4.6 Functional Significance of Twist Phosphorylation by CK2   
 
4.6.1. Twist Phosphorylation by CK2α Changes the Stability of Twist  
 
        Because our earlier data show that IL-6 stimulation leads to stabilization of Twist 
and CK2, mediates the signal, by associating with and phosphorylating Twist, we next 
examined whether or not the stability of Twist is affected  by site-directed mutagenesis of 
the putative CK2 phosphorylation sites of Twist . As discussed in section 4.5, when the 
amino acid serine (S) is substituted by alanine (A), which has a similar structure except 
the –OH residue on the second carbon is replaced with a methyl group, phosphorylation 
can not occur  and therefore functionally mimics the unphosphorylated serine. When 
serine is substituted with aspartic acid (D), a negatively charged amino acide side, it   
functionally mimicks a phosphorylated serine. Following these principles, hypo- and 
hyper-phosphorylated mimicking mutants of Myc-Twist constructs were generated as 
S18 and S20 were substituted with alanine (S18,20A-Myc-Twist) or aspartic acid 
(S18,20D-Myc-Twist) by site-directed mutagenesis.The protein degradation rate of WT 
Twist or its phosphorlation site mutants were examined after the treatment with 
translation inhibitor CHX and the half life of Twist and its isoforms was determined. The 
results from experiments performed in triplicate   are shown in Figure 4.21A. The 
numbers below each western blot are the relative intensity of the band by densitometric  
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measurement as determined from Image J. Figure 4.21B represents the protein amount (in 
log axis) versus time of CHX treatment. Figure 4.21C is the summary of the half-lives of  
WT –Myc-Twist and Twist mutants from the three experiments. The average half-lives 
for Twist S18,20D, Twist 18,20A and WT-Twist are 32.3± 5.94h, 9.3±0.64h and 
13.4±0.92 h respectively. All P values are less than 0.05 by comparing means from any 
two groups with student t test.  
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A.  
 
 
 
 
 
 
 
 
B. 
 
 
 
 
C.  
 
 
 
 
 
Figure 4.21 Twist stability is affected by CK2 phospho-modification 
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Figure 4.22 The in vivo Ubiquitination Assay in 293T transient transfectant lysates   
        Since Twist has been reported to be degraded through ubiquitin/proteasome pathway, 
we next examined whether or not there is increased ubiquitination in the hypo-
phosphorylated Twist mutant. In this in vivo ubiquitination assay, 293T cells were 
transfected with WT- or mutant- Myc-Twist as well as HA-tagged ubiquitin expression 
plasmids for 48 hours. Then the cell lysates were collected and immunoprecipitated with 
Myc tag , electrophoresed, transferred, and immunoblotted with with HA or Myc 
antibodies. As shown in Figure 4.22, there is hyperubiquination of the S18,20A Twist in 
293T cells when co-transfected with HA-tagged ubiquitin relative to WT-Twist and  
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actin
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S18,20D –Twist. The result between WT and S18,20A –Twist groups was consistently 
observed in three independent experiments, supporting that the phospho-modification 
may affect the stability through affecting its ubiquitination status.  
 
4.6.2. The Interaction Between Twist and E12 Protein is Increased after IL-6 
Treatment 
        Previous studies have shown that bHLH proteins form active dimers that can bind to 
the regulatory elements of downstream genes (Firulli and Conway, 2008).   Therefore, we 
examined whether there is an association between Twist and its dimer partner, the E2A 
protein (E12) in the presence of IL-6. As shown in Figure 4.23, the total amount of 
endogenous E12 that was co-immunoprecipitated with WT-Twist was increased in the 
Myc-Twist over-expressing HN31 cell lysates after a short treatment (30 min) with IL-6.  
 
 
 
 
 
 
 
 
Figure 4.23 The interaction between Twist and E12 is increased after IL-6 treatment 
E12
Myc
E12
Myc
?-actin
IP: Myc
Lysate
IgGIL-6                                          - +           - +           - +           - +
Vector WT S18,20A S18,20D
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From this blot, comparison between groups can not be made since the basal levels of E12 
in different lines are not equal. However, the total amount of E proteins associated with 
S18,20D is higher than those with wild type or S18,20A. The evidence in this figure 
suggests that IL-6 may play some role in mediating E12 and Twist interaction.   
 
 
4.6.3 The Motility of SCCHN Cells is Increased by Expression of Forced T/E 
Hetero-dimer  
      
        Given that the both E12 and Twist are involved in the EMT process, trans-well 
migration assays were performed  in HN31-SCCHN cells transiently expressing either 
WT-Twist, E12, or both, the forced T/T homodimer, or the T/E heterodimer   (The T/T 
and T/E dimer constructs are a gift from Dr. Spicer,Maine Medical Center) (Connerney et 
al., 2006). The scheme of the construct design of the forced dimers is shown in Figure 
4.24A. The western blot after transfection for each condition is shown in Figure 4.24B. 
The counted migrated cells in Boyden chamber migration assay is shown in Figure 4.24C. 
  
        As shown in Figure 4.24C, over expression Twist or E12 increased the amount 
migrated cells relative to the control vector. However, increased expression level of Twist  
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does not further increase cell migration, indicating the existence of another rate-limiting 
factor rather than Twist. Although co-expression of both Twist and E12 did not show 
further increases in motility, there is a statistically significant difference between the 
forced T/T and T/E groups, suggesting a different transcription consequence between the 
two groups.   
 
A.                                                              B.  
 
 
 
 
 
C. 
 
 
 
 
 
 
Figure 4.24 The motility of HN31 SCCHN cells is increased by expression of forced 
T/E heterodimer. *: represents P value < 0.05 
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4.6.4 Twist Phosphorylation Promotes Cell Motility in vitro  
        We next examined the effects of IL-6 treatment on OSC-19 SCCHN cell motility as 
measured by wound healing assay. Figure 4.25A shows the representative pictures before 
(0h ) and 12h after indicated treatment and the migratory distance during the 12h 
treatment was quantified by Image J and expressed as relative values (set control= 100) in 
Figure 4.25B. The experiment was done in duplicate and at least 12 measurements in 
each well were analysed.   
A. 
 
 
 
B. 
 
 
 
 
 
 
 
Figure 4.25 The motility of OSC-19 SCCHN cells is promoted by IL-6 and blocked 
by the CK2 inhibitor, DMAT.  
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We next examined the effects on cell motility of shTwist in the presence of IL-6. As 
shown in Figure 4.26, IL-6 increases the cell motility in the trans-well assay, which is 
consistently seen in the wound healing assay. In this 22h trans-well assay, blocking the 
expression of Twist decreases the cell migratory ability in the absence or presence of IL-6, 
suggesting that the IL-6-mediated cell migration is, only in part, through Twist since in 
the absence of Twist, the cells still could respond to exogenous IL-6 stimulation.   
 
Figure 4.26  IL-6 promotes OSC-19 SCCHN cell motility, in part, through Twist  
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        Then we examined the motility of HN31 SCCHN stabling expressing WT—Myc-
Twist, and Twist mutants. As shown in figure 4.27, over-expression of WT Twist but not 
S18,20A Twist in both OSC-19 and HN31- SCCHN cell lines promotes cell migration 
relative to the control. Furthermore, over expression of S18,20D Twist further increases 
the motility relative to WT or S18,20 A Twist, suggesting that this mutation further 
promotes cell motility.  
 
 
A.  
 
 
 
 
 
 
 
 
 
Figure 4.27 Overexpression of Myc-WT- Twist, not Myc-S18,20A –Twist promotes 
the motility of  SCCHN cells 
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(continued) Figure 4.27 Over expression of Myc-WT- Twist , not Myc-S18,20A –
Twist promotes the motility of  SCCHN cells 
In Figure 4.27A, the experiment was performed with OSC-19 SCCHN cells after 
transient transfection by electroporation for 48 h. Then the cells were trypsinized and re-
plated for subsequent trans-well migration assay. In Figure 4.27B, the experiment was 
performed using  HN31-SCCHN cells .The representative images of the migrated cells 
from the corresponding trans-well membranes are shown in the lower and middle panels 
of Figure 4.27 A and B respectively. The quantitative data are shown in the upper panels 
and expressed as mean +/- SEM of the cell counts from each group in lower-powered 
field microscopic exams. *P<0.05 .  
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4.6.5 The effect of Twist phosphorylation by CK2 on lymph node metastasis in vivo  
        To investigate the potential impact of the over expression of Twist and its phospho-
modificated isoforms on the incidence of lymph node metastasis in a murine orthotopic 
model of tongue cancer, we inoculated a small number of cells from the HN31 stable-
Twist transfectant lines (10,000 cells / mouse) into the lateral tongues of nude mice and 
observed them for tumor growth and lymph node metastasis for 8 weeks.  
 
        During the 8-week period of observation, the tumorigenecity was found to be 8/10 
and 7/10 mice in the control and S18,20A –Twist groups respectively and is markedly 
decreased in the WT-Twist and S18,20D –Twist group (Both are 4/10 ). The tumors in 
the S18,20A Twist group grew the biggest among the 4 groups (P<0.05) as summarized 
in Table 12. 
 
 
 
 
 
 
Table 12 The volumes and rates of tumor formation in mice 8 weeks after inoculated 
orthotopically in the tongue with 10,000 HN31 cells stably expressing wild- type 
Twist and its mutants .  
7/10
90.1 ± 90.9
7/10
A-Twist
6/106/108/10Microscopic tumor 
41.5 ± 29.118.3 ± 9.432.6 ± 25.6Ave tumor vol at sac 
(mm3) 
4/104/108/10Tongue Tumor formation
D-Twist Twist Control
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      However, at sacrifice, there are more grossly detectable neck lymph nodes in WT- 
Twist and S18,20-Twist group as shown in Figure 4.28. A total of 30 and 25 lymph nodes 
were found in WT-Twist and S18,20 D Twist group respectively; Only 14 and 10 lymph 
nodes were found in the  control  and S18,20A –Twist group respectively despite the 
higher rates of tumorigenecity and bigger average tumor volumes in these two groups.  In 
contrast, in some cases in WT-Twist and S18,20D Twist groups, they had unusually 
enlarged lymph nodes despite  the lack of detectable tumor formation in the tongues.  
 
        Microscopically, only non-specific inflammation was noted in the enlarged lymph 
nodes, as no cancer metastasis were found in these enlarged lymph nodes. As result, the 
total lymph node metastasis rate, as determined by microscopic examination, is 1/10, 
1/10, 2/10, and  1/10 in control, WT-Twist, S18,20A Twist, and S18,20D Twist group 
respectively. No statistical significance was found.  
 
        Although there is no statistical significant difference between groups in the lymph 
node metastatic rate, the tumor size in each group did differ.   
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Figure 4.28 Representative pictures of the cervical lymph nodes at sacrifice (Right) . 
The dissected nodes and tongues with tumors are listed at left panel for comparison.  
Mouse inoculated with WT-Twist, not S18,20A, over expression HN31 stable lines 
had more grossly detectable neck lymph nodes.  
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        We next examined the incidence of lymph node metastasis 14 days after inoculation 
of a larger number of cancer cells (50,000 cells/ mouse) into the tongues of nude. In this 
experiment, tumorigenesis was 100% in all mice group as listed in Table 13. There is no 
statistical difference in the tumor sizes between except the S18, 20D Twist group, which 
is less that the other groups (Figure 4.29).   
 
 
 
 
 
Table 13 The volumes and rates of tumor formation in mice 2 weeks after inoculated 
orthotopically in the tongue with 50,000 HN31 cells stably expressing wild- type 
Twist and its mutants  
 
 
 
 
 
 
Figure 4.29 In vivo tongue tumor volume of each HN31 stable lines 2 weeks after the 
inoculation with 50,000 cells inoculation. 
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        For this set of experiments, the microscopic lymph node metastasis per group 
(10mice) is listed in Table 14. There is a tendency towards increased lymph node 
metastasis in the WT-Twist and S18,20D Twist  groups (3/10 and 5/10 relative to 2/10 in 
the control and 1/10 in the S18,20A group) . However, there is no statistical significance. 
The representive microscopic lymph node metastasis in H&E staining and cytokarin (Lu-
5) staining of each group is shown in Figure 4.30.  
 
 
 
 
 
 
 
 
 
Table 14 Incidence of lymph node metastasis 2 weeks after inoculation with a higher 
cell number ( 50,000 cells) 
 
5/10Twist S18,20?D
1/10 Twist S18,20?A
3/10Twist wild-type
2/10 control
LN metastatic rate 
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Figure 4.30 Representative pictures of immunohistochemical staining (H&E and 
cytokeratin Lu-5) of tumors and metastatic lymph nodes in each group of mices that 
was incoculated with 50,000 cells 
 
 
        In addition to lymph node metastasis, there was increased histiocyte infiltration 
observed in the lymph nodes of the S18,20D-Twist group, which was not observed in 
other three groups. Usually, histiocytosis in the reactive lymph adenitis suggests a foreign 
body reaction, such as in infection like tuberculosis or early cancer cell infiltration.  
 
Lymph node Tongue tumor Lymph node
Cytokeratin
staining H&E staining 
(1) control
(2) WT-Twist 
(3) S18,20A- Twist 
(4) S18,20D- Twist 
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Since histiocytosisis only observed in the S18,20D-Twist group and the mice are 
generally healthy and mainatained in a pathogen free environment, early cancer cell 
infiltration is highly suspected.  
 
 
 
 
 
 
Figure 4.31 Representative H&E staining of 2 lymph nodes from the S18,20D Twist 
group shows increased histiocyte infiltration. 
 
4.6.6  Conclusions and Discussion 
 
        In this section, we confirmed that phospho-modification of Twist by CK2 may play 
a role in mediating its stability as the S18,20D phosphorylated-mimetic Twist mutant has  
the highest half-life as compared to S18,20A mutant and wild-type Twist.  There is 
increased HA-tagged ubiquitin conjugation with the S18,20A Twist mutant compared to 
wild-type and S18,20D mutant, suggesting increased ubiquitination in the less stable and 
unphosphorylated-mimmetic mutant Twist.  We also confirmed that IL-6 promotes the  
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cell motility in SCCHN cells in vitro. The IL-6 mediated cell motility is blocked by either 
the use of CK2 inhibitor or shTwist, indicating both CK2 and Twist are important in 
mediating this phenomenon. Further, the CK2 hyerphosphoric mimic mutant Twist 
(S18,20D), and not S18,20A-Twist,  can increase the cell motility, supporting that IL-6 
mediating cell motility is through Twist by CK2 phosphorylation.  
 
        The mechanisms of how Twist phoaphrylation promotes cell motility remain unclear. 
It has been reported that Twist promotes the motility of breast cancer cells through 
transcriptionally upregulating the expression of AKT2 (Cheng, GZ et al., 2007). However, 
in either 293T cells or SCCHN cells, we were not able to demonstrate the upregulation of 
AKT2 promoters by different Twist plasmids  in a luciferase promoter assay. Another 
potential target, E-cadherin suppression, which has been reported to result from Twist 
over expression in breast cancer cell lines (Ynag J et al., 2004), was not observed in the 
cell lysates from the Myc-Twist HN31 stable lines or transiently over expressing HA-
Twist in the OSC-19 cell line. These negative results may be due to the different cell line 
systems used. To solve the problem, we could use comparative transcriptional profiling 
such as cDNA microarrays to identify and validate the potential downstream targets of 
Twist phosphorylation.       
 
        On the other hand, our preliminary data showed there might be increased interaction 
between Twist and E12 after brief treatment of IL-6 in SCCHN cells. Given the     
 128
Results 
 
background that E proteins have been found to participate in EMT (Thiery, JP, 2005), 
which is associated with regulation of cell (Lluis FE, et al., 2005), our data, although 
preliminary,  suggests cooperatve Twist and E protein transcriptional regulation in 
response to cytokine signals. From computational analysis of the E12 protein sequence, 
there are several CK2 phosphorylation consensus motifs. Further studies need to be 
performed to determine whether or not E12 is also phosphorylated by CK2 and how the 
phosphorylation of E12 and Twist might work in concert to regulate EMT could enhance 
our current understanding of the mechanisms of EMT regulation by Twist. 
 
        Although the in vivo experiments using different number of injected cells (10,000 
and 50,000 respectively) in the orthotopic xenographic tongue cancer model did not show 
statistically significant differences in the incidence of lymph node metastasis, these 
studies might be confounded by endogenous Twist, the tumorigenecity or residual 
immune reaction in the lymph node of athymic nude mice.  
 
        Our mice experiments reveal the limitations of in vivo studies to demonstrate the 
small difference observed in vitro. For a 30-40% difference in cell migration, we may 
need 200 mice per group to have enough statistical power, which is not feasible for 
experimental animal studies. Another approach to studying the role of stable wild type 
and phosphos mutantTwist expression and is to utilize different SCCHN cell lines. 
Experimentally, HN31 SCCHN, which was used for establishing stable cell lines due to 
the high transfection efficiency by electroporation, is a very resistant and aggressive cell 
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line. Also, these cells express higher levels of endougenous Twist than other SCCHN 
cells which may interfere with the observations of specific phenotypes for mutant Twist.  
At this aggressive background, over-expression Twist in such cell line may only 
minimally increase cellular invasiviness, which may result in insignificant findings in 
vivo.    
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V. DISCUSSION AND FUTURE DIRECTIONS 
 
        Over expression of Twist, which functions as a master regulator of tumor metastasis, 
has been correlated with advanced tumor metastasis, advanced tumor stage and poor 
prognosis in many types of cancer, including SCCHN (Yang and Wu, 2008; Kwok et al., 
2005). In addition to facilitating cell motility both in vitro and in vivo, Twist has also 
been shown to enhance apoptosis inhibition, angiogenesis and chemoresistance in vitro 
(Cheng et al., 2007). Although a number of downstream transcriptional targets of Twist 
have been found, the control of Twist expression at post-transcriptional level has been 
less well studied. The discrepancy between Twist mRNA expression and Twist protein 
expression in a comparative analysis in both embryo and adult tissues indicates that Twist 
expression is regulated at the post-transcriptional level.(Gitelman, 1997; O'Rourke and 
Tam, 2002). In this project, we have shown that IL-6 treatment increases Twist protein 
expression through CK2 phosphorylation of Twist. This post-transcriptional modification 
can stabilize the Twist protein, allowing Twist to regulate cell motility. 
 
5.1. The Importance of Twist Phosphoregulation  
        Although Twist phosphoregulation has been described in studies for Twist mutations 
in patients with Saethre-Chotzen syndrome (SCS)(Firulli et al., 2005), an autosomal 
dominant disorders of craniosynostosis , the role of phosphoregulation of Twist in cancer  
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cells, to our knowledge, has only been discussed in one study that addresses the p53- 
related anti-apoptotic function in the presence of Akt phosphorylation of Twist 
(Vichalkovski et al., 2010).  In SCS, Twist dimerizes differently depending on whether it 
is phosphorylated by protein kinase PKA or dephosphorylated by the trimeric protein 
phosphatase 2A, at site T121/S123. Since Twist has been shown to play both positive and 
negative roles in mesenchymal differentiation, it is believed that heterodimerization with 
different partner proteins plays an important role in modulating its transcriptional 
function during cranial bone development (Connerney et al., 2008; Connerney et al., 
2006).  
 
        Interestingly, not only Twist, but also its dimer partner, E12, are involved in the 
regulation of EMT (Connerney et al., 2006; Perez-Moreno et al., 2001). In this project, 
we have shown that he increased E12 protein was co-immunoprecipitated with WT-Twist 
in the presence of IL-6 in SCCHN cells (Figure 4.22). The data, although still preliminary, 
suggests that the phospho-modification of Twist may affect its dimerization with E12. A 
similar search for the potential CK2 phosphorylation site on the E12 protein with 
computational prediction, reveal that there are several CK2 sites found on this protein. 
Since E protein has been known as a phospho-target of p38 MAPK (Lluis et al., 2005), it 
would be interesting to study if E12 is also a target of CK2 and how the CK2 
modification effects the interaction between Twist and E12. In our transwell migration 
study, cell motility is marked increased in the forced T/E dimerization relative to wild  
 132
Discussion and Future Directions  
 
type Twist group, however it is not  seen in the co-transfection with Twist and E12. 
Whether phosphorylation plays a role in mediating the dimeriation and transcription 
activity needs further investigation. Whether the transcriptional activity of Twist is 
modified by CK2 phosphorylation remains to be explored but could provide useful 
information for many labs studying EMT since the inconsistent observation across cell 
lines, which have raised controversies, may be  reconciled thorough the phospho-
modification of EMT proteins.   
 
5.2. The Role of CK2 in Response to Cytokine Treatment   
        In this project, we chose to focus on the cytokine IL-6, which was originally 
regarded as a regulator of immune and inflammatory responses and its expression is 
detectable in many epithelial tumors and correlates with unfavorable clinical outcomes  
(Nishimura et al., 2000; Bachelot et al., 2003; Schafer and Brugge, 2007; Colomiere et al., 
2009; Allen et al., 2007). There is also evidence that IL-6 plays a role in tumor 
progression of EGFR mutated lung cancer (Gao et al., 2007). However, since SCCHN 
tumorigenesis and progression has long been known to be influenced by multiple growth 
factors and cytokine signaling factors other than IL-6, we analyzed the post-
transcriptional regulation of Twist in response to other SCCHN-relevant 
cytokines/growth factors and found that the stabilization of Twist is not IL-6 restricted 
(data not shown). Twist can also be upregulated within minutes after EGF and VEGF-C 
treatment in SCCHN lines.  Since CK2 is also reported as a phosphorylation target in the  
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EGFR signaling pathway in neuroblastoma lines (Ji H et al., 2009), it would be 
interesting to validate whether or not CK2 is a downstream to these pathways in SCCHN 
lines because CK2 plays an important role in mediating the activity of NF-κB, an 
important mediator in cytokine pathways and of prognostic value in SCCHN.  
 
5.3. Connecting Inflammation, Twist, and Cancer progression    
        Our study, which links Twist, an important mediator for tumor progression, with 
inflammatory cytokine IL-6 and CK2, may contribute to the current knowledge regarding 
inflammation and the tumor progression. SCCHN tumorigenesis often arises in the  
inflammation within the pre-malignant lesions, leukoplakia, erythroplakia, or oral 
submucous fibrosis. CK2 has been reported to be activated by multiple inflammatory 
cytokines and growth factors related to inflammation and can regulate the activity of NF-
κB (as reviewed in section 1.3). Activated CK2 is correlated with chronic inflammatory 
disease such as glomoeruloenphritis and SLE, indicating the biological importance of 
CK2 in inflammation. In this study, we add Twist to the list of CK2 phosphorylation 
targets. Since Twist can mediate the migration of both embryonal cells and cancer cells, 
the link between IL-6 and CK2 may undersore the importance of inflammation to cancer 
development and progression.  
 
          Our experiments show that despite high levels of cancer-secreted IL-6 in the 
cultured supernatants, these caner cells still can respond to exogenous IL-6 and undergo  
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partial EMT, indicating that cytokines from the tumor microenvironment can promote 
EMT and tumor progression. Recent studies showed the cytokines such as IL-8 secreted 
by tumor cells could further attract IL-6 secreting neutrophils to tumors resulting in a 
mutually beneficial microenvironment for both immune cells and cancer.    
 
        Although some of the process may be irreversible (i.e. mutation), however, some of 
them, such as the Twist expression by IL-6 stimulation, may be reversible if CK2 kinase 
activity is blocked. Although EMT in cancer may be induced in the dysregulated 
inflammatory response, our understanding of molecular mechanisms involved in this 
process may provide insight for new strategies to reverse the process.  
 
5.4. Targeting CK2 as an Anti-cancer Therapy  
        In this report, we also showed that the level of Twist expression can be manipulated 
using a pharmacological approach with an inhibitor to CK2, suggesting that CK2 could 
be a useful therapeutic target in patients with SCCHN. CK2 is a highly conserved and 
ubiquitously expressed serine/threonine kinase, which consists of catalytic ( αα, α’α’, or 
αα’) and two β regulatory subunits (section 1.3.3 ) . CK2 was recently described as a 
“master kinase” because it controls the activity of many other kinases and regulates many 
important cellular process such as cell cycle, transcription, survival and viral infection. 
CK2 is overexpressed in multiple forms of cancer and its expression level has been 
correlated with prognosis in cancers (Lallemand-Breitenbach and de, 2006; Charoenrat et  
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al., 2004; Gapany et al., 1995). In addition, in a mouse model, silencing the expression of 
CK2 in SCCHN suppresses tumor growth and metastases (Ahmad et al., 2005; Ahmed et 
al., 2002). Because many important regulatory cellular proteins are targets of CK2 
(Lallemand-Breitenbach and de, 2006) and CK2 is oncogenic in transgenic mice 
(Litchfield, 2003), it is not surprising that CK2 has previously attracted attention as a 
potential target for therapy. Currently, an oral CK2 inhibitor is available and is being 
investigated clinically (Perea et al., 2008; Solares et al., 2009); further preclinical and 
molecular studies are needed to define the therapeutic potential of CK2 in treating 
patients with SCCHN.   
 
5.5  Conclusions and Future Directions  
        Twist, a bHLH family transcription factor, plays important roles in the control of 
cell survival, differentiation and motility. Despite the clinical correlation of Twist over -
expression with poor prognosis in patients with a varienty of cancers, the mechanisms by 
which Twist levels are regulated post-transcriptionally are less well understood. We 
provided evidence that the expression level of Twist is stabilized by IL-6 stimulation 
through CK2 phosphorylation on Twist at residue S18 and S20. The phosphorylation not 
only increases its stability but also promotes cancer cell motility.  
 
        Our preliminary data also show that there is increased heterodimerization between 
Twist and E12 following IL-6 treatment, which may change the transcriptional profile to  
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promote aggressive cellular function. Since there have been reports showing that E12 is a 
phospho-target of p38 MAPK and there are several putative CK2 phosphorylation sites 
within the E12 protein seqence, it is conceivable that phospho-modification of E12 
coould play an important role in EMT and dimerization with Twist.  Further investigation 
is clearlyneeded to discern the roles of E12 and Twist in SCCHN tumor progression.   
 
        Our findings support previous studies that cytokines can regulate the EMT of cancer 
cells. The finding of CK2 in mediating these effects in SCCHN cells suggest that this 
kinase could be an interesting target for therapy.  This is important since the progress of 
molecular targeting treatment for SCCHNlags behind other cancers and there is an urgent 
need for innovative therapy for SCCHN patients.  
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